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ABSTRACT 
Human rhinoviruses (HRV), belonging to the family Picornaviridae, are small, non-enveloped 
viruses with an icosahedral capsid and are one of the main causative agents of the common cold. 
After infection, the single-stranded RNA genome of positive sense containing one large open reading 
frame is directly translated into a polyprotein, which is subsequently processed to yield mature viral 
proteins. The first cleavage event is performed by the chymotrypsin-like proteinase 2Apro in HRVs 
which cleaves between the C-terminal of the preceding protein VP1 and its own N-terminus.  
Here, we investigate the different substrate specificities of the 2Apro of HRV1A and HRV14, two 
human rhinoviruses from the different genetic groups, A and B, that show a great variation in the 
amino acid sequence at the cleavage site of the 2Apro.  
Initially, we analyzed the effect of mutations in the cleavage site on the self-processing. We 
found that HRV1A 2Apro is not able to accept the full HRV14 2Apro cleavage site in vitro as monitored 
by translation in rabbit reticulocyte lysates (RRL). It was further shown that these multiple mutations 
also severely impair the self-processing in vivo, as no viral offspring could be generated after the 
transfection of corresponding RNA in HeLa cells. Subsequently, we demonstrated that substitutions 
on both side of the cleavage junction are necessary to stop proteolytic processing in vitro. Mutating 
residues on only one side of the 2Apro cleavage junction resulted only in a slightly delayed self-
processing in vitro.  
In the next step, we tried to find the minimal number of HRV14 residues required to abrogate 
proteolytic activity of HRV1A 2Apro. We showed that changing residues P2, P1 (threonine and alanine) 
and P2’ (proline) at the 2Apro cleavage junction of HRV1A with corresponding residues of HRV14 
(serine, tyrosine and leucine, respectively) was enough to prevent the HRV1A 2Apro from processing. 
This sub-optimal cleavage site was introduced into a HRV1A full length clone and HeLa cells were 
transfected with viral RNA. We were able to identify several representatives of two different escape 
mutants in response to this cleavage site. Most escape mutants had changed tyrosine at P1 to 
cysteine, which was rather surprising, as tyrosine was normally very well accepted at this position in 
the wild-type HRV2 2Apro (HRV1A is closely related to that of HRV2) cleavage (Sommergruber et al., 
1992). Another response was to mutate leucine, at P2’, back to the wild type proline. 
In addition, we exchanged the highly conserved glycine at position P1’ with the slightly larger 
amino acid alanine which also completely stopped the self-processing reaction of the HRV1A 2Apro in 
vitro. All escape mutants isolated had reverted alanine back to the wild type glycine. These in vivo 
experiments demonstrate that glycine is the only amino acid accepted at this position in the cis 
cleavage reaction of HRV1A 2Apro. In our model, the HRV2 2Apro tyrosine 85, which is rotated after the 
binding of the substrate to the enzyme, and the subsequent formation of a hydrogen bond between 
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threonine at position P2 (substrate) and serine 83 (enzyme) would block the access of any bulkier 
molecule at the P1’ site other than glycine. Any residue bigger than alanine would also be blocked by 
leucine 19; however, alanine would be small enough to not be blocked by leucine 19.  
As previous results have suggested that the activity of the 2Apro is influenced by the 
neighboring protein 2B in vitro (Kirkegaard and Neubauer, both pers.comm.), we aimed to transfect 
HeLa cells with the RNA containing the mutation I94N in the 2B in order to possibly be able to isolate 
escape mutants. However, we showed that the activity of the HRV14 2Apro is not influenced in vivo by 
the 2B I94N mutation. We could not detect any difference in vivo neither in regard to plaque 
phenotypes nor to growth kinetics compared to wild type HRV14. We further isolated two escape 
mutants having an additional mutation in the 2Apro (M17T and P4H). These second site revertants 
showed reduced growth kinetics compared to wild type HRV14 and single HRV14 2B I94N mutant. 
Therefore, we concluded that these mutations were probably introduced incidentally by the error-
prone RNA polymerase.  
Furthermore, previous experiments have shown that HRV14 2Apro is not able to accept an 
arginine (in place of a tyrosine) in the P1 position of the cleavage site (Sousa et al., 2006). We 
therefore again tried to transfect HeLa cells with RNA containing the mutation Y289R in the VP1 in 
order to search for escape mutants. Here, we showed that the activity of the HRV14 2Apro is 
influenced in vivo by the VP1 Y289R mutation also. Much smaller plaques were observed when 
transfecting cells with the VP1 Y289R mutant than with the wild type HRV14. In addition, viral growth 
was not only delayed but did also not reach the same amount of maximum yield. However, the 
difference was only about 1 log, which does not explain the very small plaque sizes of this mutant. 
We therefore assume that this mutation might lead to a defect in spreading or lysis as it affects the 
sequence of the capsid protein VP1.  
The work in this thesis shows that exchanging combinations of residues on both side of the 
cleavage junction are necessary to inhibit the intramolecular cleavage of the HRV1A 2Apro. However, 
the replacement of one side is enough to recover proteolytic activity of this enzyme. We show that 
cysteine at the position P1 of the cleavage junction is accepted by the HRV1A 2Apro in vivo. Although 
the VP1 Y289R mutation was shown to inactivate the HRV14 2Apro in vitro, we demonstrate that is 
not the case in vivo. However, a small plaque phenotype can be observed which might be due to the 
presence of arginine at the P1 position of the cleavage junction of HRV14 2Apro. We conclude that it is 
further necessary to investigate substrate specificity of both HRV1A and HRV14 2Apro. However, from 
what we can say so far, both proteases display distinct substrate specificities; thus, specific inhibitors 
will be necessary for each protease if they are to be used to treat the common cold. 
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ZUSAMMENFASSUNG 
Humane Rinoviren (HRV), welche zu der Gruppe der Picornaviridae gehören, sind die Erreger 
die Schnupfen und Erkältung beim Menschen erzeugen. Die sehr kleinen Viren besitzen keine 
Lipidschicht als Hülle und weisen die Symmetrie eines Ikosaeders auf. Als genomisches Material 
besitzen sie eine einzelsträngige RNA mit positiver Polarität, die nur einen offenen Leserahmen 
besitzt. Von diesem wird ein langes Polyprotein abgelesen, das sogleich von viralen Proteasen 
prozessiert wird um fertig entwickelte, virale Proteine zu erhalten. In HRV wird der erste Schritt 
dieser Prozessierung von der Chymtrypsin-ähnlichen Protease 2Apro durchgeführt, die sich selbst in 
einer intramolekularen Reaktion zwischen dem C-Terminus des vorrangehenden Proteins VP1 und 
ihrem eigenen N-Terminus abspaltet.  
In dieser Arbeit wird die unterschiedliche Substrat-Spezifität von HRV1A und HRV14, zwei aus 
unterschiedlichen genetischen Gruppen stammenden HRV (A und B), untersucht. Die 
Aminosäuresequenz der Spaltungsstelle der 2Apro dieser beiden HRVs ist besonders unterschiedlich.  
Am Anfang analysieren wir den Effekt unterschiedlicher Mutationen in der Schnittstelle auf die 
Selbstprozessierungsreaktion. Dabei finden wir heraus, dass die 2Apro von HRV1A nicht in der Lage ist, 
die Schnittstelle der 2Apro von HRV14 zu akzeptieren, wenn sie gänzlich ausgetauscht wird. Wir 
beobachten den Spaltungsprozess während der Translation mit Hilfe von Kaninchen 
Retikulozytenlysaten. Weiters zeigen wir, dass diese vielen Mutationen in der Spaltungsstelle nicht 
nur die Selbst-Prozessierung in vitro stark beeinflussen, sondern auch kein viraler Nachkomme nach 
der Transfektion der entsprechenden RNA in HeLa Zellen generiert werden kann. Im Rahmen dessen, 
demonstrieren wir, dass Veränderungen auf beiden Seiten der Spaltungsstelle notwendig sind, um 
die proteolytische Aktivität in vitro zu stoppen. Wenn man nur eine Seite rechts oder links des 
Spaltungspunktes austauscht erhält man lediglich eine zeitverzögerte Selbst-Prozessierung in vitro.  
Im nächsten Schritt, versuchen wir die minimale Anzahl an Aminosäuren, welche notwendig 
sind um die proteolytische Aktivität der 2Apro von HRV1A zu stoppen, herauszufinden. Wir zeigen, 
dass die Veränderung von den Aminosäuren an den Stellen P2, P1 (Threonin und Alanin) und P2‘ 
(Prolin) der HRV1A 2Apro Prozessierungsstelle, wenn sie durch die entsprechenden Aminosäuren der 
HRV14 2Apro an diesen Stellen (Serin, Tyrosin und Leucin) ausgetauscht werden, ausreichen um die 
Selbst-Prozessierung zu inhibieren. Diese nicht-optimale Spaltungsstelle wird in den kompletten 
HRV1A Klon eingefügt. Daraufhin werden HeLa Zellen mit dieser viralen RNA transfiziert. Es gelingt 
uns zwei unterschiedliche Arten von sogenannten Fluchtmutanten als Antwort auf die 
Spaltungseinschränkung der veränderten Spaltungsseite, zu isolieren. Die meisten Fluchtmutanten 
haben anstelle des Tyrosins an der P1 ein Cystein. Dies ist durchaus erstaunlich, da in 
vorangegangenen Studien ein Tyrosin an dieser Stelle der Spaltungsseite der HRV2 2Apro, die sehr 
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ähnlich wie die HRV1A 2Apro ist, von dieser ausgezeichnet akzeptiert wurde (Sommergruber et al., 
1992). In anderen Mutanten konnten wir eine Rückänderung von Leucin zur ursprünglichen 
Aminosäure, dem Proline, beobachten.  
Zusätzlich vertauschen wir das stark konservierte Glycin an der Stelle P1‘ mit der nächst 
größeren Aminosäure, dem Alanin. Auch diese Veränderung verhindert die Spaltungsreaktion der 
2Apro von HRV1A in vitro. Alle isolierten Fluchtmutanten haben dieses Alanin zurück zu Glycin 
gewandelt. Diese in vivo Experimente demonstrieren, dass Glycin die einzig akzeptierte Aminosäure 
an dieser Stelle in der intramolekularen Spaltung der 2Apro von HRV1A ist. In unserem Model dreht 
das Tyrosin an der Stelle 85 in der HRV 2Apro, nach der Bindung des Substrats und der darauf 
folgenden Bildung einer Wasserstoffbrücke zwischen dem Threonin an der Stelle P2 des Substrats 
und dem Serin an der Stelle 83 des Enzyms hinaus und blockiert somit irgendeine umfangreichere 
Aminosäure als Glycin an der P1‘ Stelle. Eine größere Aminosäure als Alanin wird zusätzlich auch von 
Leucin an der Stelle 19 blockiert. Jedoch wäre Alanin klein genug um nicht von diesem Leucin 
blockiert zu werden.  
Darüber hinaus beschäftigen wir uns auch mit der 2Apro von HRV14, da vorrangegangene 
Ergebnisse zeigen, dass die Aktivität der 2Apro von dem benachbarten Protein 2B in vitro beeinflusst 
wird (Kirkegaard und Neubauer, pers.comm.). Wir erhofften uns, durch die Transfektion dieser RNA, 
welche die Mutation I94N im 2B Protein erhielt, Fluchtmutanten isolieren zu können, welche uns 
einen Hinweis auf strukturell wichtige Aminosäuren geben. Wir zeigen jedoch, dass die Aktivität 
dieser 2Apro in vivo nicht von der Mutation im 2B Protein (I94N) beeinflusst wird. Wir können keinen 
Unterschied zwischen dieser Mutante und dem HRV14 Wildtyp feststellen, weder in Zusammenhang 
mit den Erscheinungsformen der viralen Plaques noch im Wachstums. Jedoch können wir zwei 
Fluchtmutanten isolieren. Da aber auf der einen Seite kein Wachstumsdefekt der Einzel-2B-Mutante 
festgestellt werden kann, und auf der anderen Seite die Fluchtmutanten eine reduzierte 
Wachstumsrate aufweisen, schließen wir daraus, dass diese Mutationen aufgrund der natürlichen 
Evolution eingefügt wurden und nichts mit unserer eingefügten Mutation zu tun haben.  
Außerdem haben weitere Experimente gezeigt, dass die HRV14 2Apro ein Arginin (anstatt 
Tyrosin) an der Stelle P1 der Spaltungsstelle nicht akzeptiert (Sousa et al., 2006). Daher untersuchen 
wir die Beeinflussung dieser Mutation (Y289R in VP1) in vivo und versuchen erneut Fluchtmutanten 
zu isolieren. Ein Unterschied in der Größe der Plaques nach der Transfektion kann festgestellt 
werden. Diese Mutante zeigt deutlich kleinere virale Plaques als der HRV14 Wildtyp. Zusätzlich ist die 
Wachstumsrate nicht nur etwas verzögert, es kann auch nie die maximale Ausbeute an Virus erreicht 
werden. Da jedoch der Unterschied nur ein Log beträgt, kann dies nicht vollständig den äußerst 
kleinen Durchmesser der Plaques erklären. Wir vermuten allerdings, dass diese Mutation zu einem 
zusätzlichen Defekt in der viralen Ausbreitung oder der Lyse führt.  
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Die Ergebnisse dieser Arbeit zeigen, dass es notwendig ist beide Seiten der HRV1A 2Apro 
Spaltungsstelle auszutauschen um die intramolekulare Spaltung zu inhibieren. Jedoch ist es in vivo 
ausreichend nur eine Seite zu verändern, um die proteolytische Aktivität der HRV1A 2Apro 
wiederherzustellen. Wir zeigen außerdem, dass ein Cystein an der Stelle P1 von der HRV1A 2Apro in 
vivo akzeptiert wird. Obwohl die Mutation im VP1 Protein (Y289R) in vitro zu einer Inaktivierung der 
HRV14 2Apro geführt hat, zeigen wir dass die HRV14 2Apro mit dieser Mutation in vivo aktiv ist. Jedoch 
können wir eine Veränderung der Plaquegröße feststellen, die wir auf das Vorhandensein von Arginin 
anstelle des Tyrosins an der Stelle P1 zurückführen. Daraus folgern wir, dass weitere Erforschungen 
bezüglich der Substratspezifität der 2Apro von HRV1A und HRV14 notwendig sind. Bis jetzt kann man 
allerdings sagen, dass beide Proteasen eine unterschiedliche Substratspezifität aufweisen, und man 
wahrscheinlich spezifische Inhibitoren gegen jede dieser Proteasen herstellen wird müssen um den 
Schnupfen zu behandeln.  
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1 INTRODUCTION 
                          
1.1 PICORNAVIRUSES 
The family Picornaviridae derives its name from the greek word pico meaning very small and 
RNA referring to their single-stranded positive-sense RNA (Semler and Wimmer, 2002). Indeed, 
picornaviruses are small viruses with a 28-30 nm diameter of their non-enveloped icosahedral capsid, 
which encloses one naked molecule of positive sense single-stranded RNA ranging from 7.2-8.5 
kilobases (kb). Well-known picornaviruses include poliovirus, human hepatitis A virus, human 
rhinovirus and foot-and-mouth disease virus. They cause a variety of diseases in human and animals, 
including poliomyelitis, hepatitis, the common cold and foot-and-mouth disease (Semler and 
Wimmer, 2002; Racaniello, 2007). 
According to the most recent taxonomy, the international committee on taxonomy of viruses 
(ICTV, 2009; Knowles et al., 2011), the family Picornaviridae contains 12 genera. These genera are: 
Aphthovirus, Avihepatovirus, Cardiovirus, Enterovirus, Erbovirus, Hepatovirus, Kobuvirus, 
Parechovirus, Sapelovirus, Senecavirus, Teschovirus and Tremovirus. Each genus is further divided 
into species containing one or more antigenically distinct serotypes ((ICTV, 2009; Knowles et al., 
2011). The high similarity of sequence and genome organization has led the former genera 
Rhinovirus and Enterovirus to be recently (2009) re-classified together into the genus of Enterovirus.  
 
1.2 HUMAN RHINOVIRUS 
This thesis deals with the substrate specificity of the proteinase 2Apro of human rhinovirus 
(HRV); therefore, the introduction is based on the Enterovirus genus.  
One of the most frequent infectious diseases in humans, the common cold, is caused by 
human rhinoviruses (Makela et al., 1998).  Although HRVs make up about 30% of all common colds 
(Monto and Sullivan, 1993), little progress in the generation of vaccines or anti-viral compounds for 
the treatment of HRVs has been made (Papi and Contoli, 2011). HRV are transmitted via the 
respiratory-salivary route and are able to infect the upper as well as the lower respiratory tract 
(Savolainen et al., 2003). Infection of the lower respiratory tract can cause more severe diseases such 
as asthma (Nicholson et al., 1993) and chronic obstructive pulmonary disease (COPD) exacerbations 
(Johnston, 2005).  
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The current taxonomy (ICTV, 2009; Knowles et al., 2011) classifies HRV in the Enterovirus genus 
of the Picornaviridae family and distinguishes between three different species: HRV-A, HRV-B and 
HRV-C (Palmenberg et al., 2010). The HRV-C species was identified in 2006 (Lamson et al., 2006; 
Kistler et al., 2007). Several studies reveal that HRV-C types induce more severe illnesses in children 
(Lee et al., 2007) and are highly prevalent and widely circulating worldwide (Renwick et al., 2007; Lau 
et al., 2009).  77 serotypes have as yet been identified to belong to the species HRV-A, 25 serotypes 
to HRV-B and 49 serotypes to the species HRV-C (http://www.picornaviridae.com/). 
HRV serotypes are classified into one of the three groups A, B and C based on genetic 
relationships. One way to cluster the serotypes A and B is according to sequence homologies in the 
viral capsid proteins VP1 and VP4 (Laine et al., 2006). Classification into HRV-C was done recently by 
sequence comparison of the VP4/VP2 region (Simmonds et al., 2010). Secondly, the A and B 
serotypes can be classified according to the receptor used for attachment and entry. Two receptors 
have been identified so far. Major group viruses, to which about 90% of all A and B serotypes belong 
to, use the intercellular adhesion molecule 1 (ICAM-1) as receptor for attachment and as catalyst for 
the subsequent viral uncoating during cell entry (Staunton et al., 1989; Rossmann, 1994; Bella and 
Rossmann, 1999). The minor group of rhinoviruses uses the low-density lipoprotein receptor (LDLR) 
as their receptor for cell entry (Hofer et al., 1994). The minor group of rhinoviruses is exclusively 
HRV-A serotypes. HRV-Cs probably use a unique cellular receptor, as propagation in cell culture is not 
very successful at present (Palmenberg et al., 2009).  
 
1.3 VIRION STRUCTURE 
1.3.1 CAPSID  
Picornaviruses have a simple structure with a spherical shape of only about 28-30 nm of 
diameter. The genomic material is tightly packed into an icosahedral capsid, consisting of an 
arrangement of 60 identical asymmetric subunits (protomers) arranged as 12 pentamers (Janner, 
2006). Each protomer consists of one copy of four structural proteins, viral protein (VP) 1, VP2, VP3 
and VP4.  During maturation of the viral particle, the precursor VP0 is cleaved autocatalytically to 
yield VP2 and VP4 (see chapter 1.4.2). These four proteins are arranged in a T=3 icosahedron 
displaying 20 threefold axes and 12 fivefold axes (Racaniello, 2007). Figure 1 shows the structure of a 
typical picornaviral capsid and a representation of the packing of viral proteins into the icosahedral 
shell. Capsid proteins VP1-VP3 form the external surface whereas VP4 is located in the interior and is 
associated by a distributed network of contacts with VP1-VP3 within a protomer (Rossmann et al., 
1985; Flint et al., 2009). 
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Although the amino acid sequences of VP1-VP3 show no identity, they share the same general 
structure. Each protein consists of an eight stranded, antiparallel β-sheet or β-barrel jelly roll. This β-
barrel forms a wedge-shaped structure. Tight protein packing allows the formation of a dense, rigid 
protein shell, that is further stabilized by the N-termini of VP1-VP4, which are covered in the interior 
of the capsid (Smyth and Martin, 2002). The C-termini of structural proteins protrude outside the 
capsid shell.  
 
 
Figure 1 Structure of picornaviruses.  Picornaviral capsids consist of 60 protomer subunits. A) Each protomer subunit is 
formed by 4 structural proteins: VP1 (blue), VP2 (green) and VP3 (red) and VP4 (yellow). VP1-VP3 form the external surface, 
whereas VP4 is located on the inner surface (Ehrenfeld et al., 2010) B) Core β-barrel architecture of picornaviral structural 
proteins forming a wedge shaped β-barrel. C) One pentamer consists of 5 protomer subunits (Ehrenfeld et al., 2010). D) 
Ribbon diagram of complete capsid containing of 12 pentamer subunits (Ehrenfeld et al., 2010). E) Schematic 
representation of complete capsid. Protomer is surrounded by black lines. VP4 is not shown as it lies on the inner surface of 
the protein shell and can be considered as extension of VP2 (Flint et al., 2009). Pictures taken from Flint et al., 2009 and 
modified with Photoshop.  
 
The crystal structure of HRV1A was determined by Kim et al. (Kim et al., 1989) and shows a 
great difference in charge distribution of amino acid residues in the “canyon”, the putative receptor 
binding site of HRV14. This difference in amino acids is probably the explanation why major group 
viruses (e.g. HRV14) and minor group viruses (e.g. HRV1A) bind different receptor groups 
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(Verdagauer et al., 2004). Although HRV1A is similar to HRV2, it is not able to bind to the human low-
density lipoprotein receptor but recognizes the murine protein, whereas HRV2 binds to both 
homologues (Reithmayer et al., 2002). A Glu residue was determined to be important for HRV1A 
recognition by exchanging parts of the human receptor with the murine homologue and monitoring 
virus binding efficiency (Herdy et al., 2004). 
These highly organized viral capsids are not only vital for the protection of the viral genome 
from the surrounding, but also play a substantial role in the recognition of cell receptors on the host 
cell, entry and release of the RNA genome (Rossmann, 1994; Flint et al., 2009).  
 
1.3.2 ENTEROVIRAL GENOME ORGANIZATION 
Enteroviral genomes are composed of a single stranded RNA molecule of positive sense and 
belong therefore to class IV of Baltimore’s classification system. Figure 2 shows the three parts of the 
enteroviral RNA: the 5’ UTR (untranslated region), the coding region and the UTR at the 3’ end. Both 
UTRs contain important structural motifs.  
 
Figure 2 Structure of an enteroviral genome. The structural proteins (VP4, VP2, VP3 and VP1) are shown in red. The non-
structural proteins (P2-P3) are shown in dark and light blue. P2 contains the protease 2A
pro
 and the accessory proteins 2B 
and 2C. P3 consists of the accessory proteins 3A and 3B, the protease 3C
pro 
and the polymerase 3D
pol
. Picture adapted from 
(Lin et al., 2009). 
 
The 5’ end (0.6-1.2 kb) of the viral genome is covalently connected to a small protein, called 
viral protein genome linked or VPg (Flanegan et al., 1977; Lee et al., 1977) through a Tyr residue, a 
conserved residue in the VPg. It has been shown that VPg plays a vital role in genome replication 
(Paul et al., 1998).  Cis responsive elements (cre) are RNA sequences that regulate expression of 
genes located on the same strand. They are often present in the 5’ UTR, but can also be found within 
the coding region and have been identified to be involved in replication and translation of viral RNA 
(Steil and Barton, 2009). It has been shown that cres are involved in VPg uridylylation which is 
assumed to serve as primer for the viral polymerase 3D in RNA synthesis (Cordey et al., 2008). 
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Another highly conserved element in the 5’ UTR is the internal ribosomal entry site (IRES) type I, 
which promotes initiation of translation from the uncapped viral genome (Rohll et al., 1994; Borman 
et al., 1995). A cloverleaf structure is also found at the 5’ end. Replication of RNA of the viral genome 
is promoted by the binding of 3CD precursor protein to the cloverleaf (Gamarnik and Andino, 1998) 
The coding region contains one single open reading frame (ORF) so that translation produces 
only one polyprotein. The open reading frame consists of three regions P1, P2 and P3. P1 harbors the 
structural proteins VP1-VP4. All non-structural proteins are derived from P2 and P3. The P2 region 
codes for the protease 2Apro and for accessory proteins 2B and 2C. The protease 3Cpro, the 
polymerase 3Dpol and accessory proteins 3A and 3B are encoded on the P3 region. Viral proteases 
cleave the polyprotein into mature proteins (Racaniello, 2007). To the rather short 3’ UTR (47 bp in 
HRV), a polyA tail is attached (Kitamura et al., 1981).  
 
1.4 ENTEROVIRAL REPLICATION CYCLE 
 The replication cycle is divided into several steps: attachment to and entry into the host cell, 
decoding of genetic information and subsequent synthesis of new genomes, followed by the 
assembly and the release of the virion particle. The picornaviral replication cycle takes place in the 
cytoplasm of an infected cell and is schematically depicted and explained in Figure 3. 
 
 
Figure 3 Schematic representation of the HRV2 replication cycle. Attachment of the native virion to the plasma membrane 
of a host cell leads to the internalization and entry of the virus particle in an early endosome. During the development to a 
late endosome, the pH inside the endosome drops which leads to the release of viral RNA into the cytoplasm. RNA is 
translated into a polyprotein that is co-translationally processed into mature viral proteins. Apart from the self-cleavage, 
several host factors are also cleaved which lead to the shut-off of host-cell translation. During RNA synthesis, the (+) strand 
RNA is copied into full length (-) strand RNA which is used to produce additional (+) strand RNA. In early infection, this RNA 
is mainly used for further translation, whereas during late infection it is packed into viral particles. Capsid proteins (VP1-
VP4) are produced during translation (not shown). The viral particles exit the cell upon lysis. Picture taken from Skern’s 
lecture on virology [1] 
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1.4.1 ATTACHMENT AND CELL ENTRY  
Picornaviral infection of a cell starts with the attachment of a virion to the plasma membrane 
of a cell. Several surface molecules have been identified to serve as cellular receptors for 
picornaviruses. The two species of human rhinoviruses HRV-A and HRV-B bind either the intercellular 
adhesion molecule 1 (Greve et al., 1989) and belong to the major group of human rhinoviruses or 
bind to members of the low-density lipoprotein receptor (LDLR) and belong to the minor group of 
human rhinoviruses (Hofer et al., 1994). The receptor used by the third, recently discovered species 
HRV-C, is not known until now.   
ICAM-1 was identified by isolating the receptor protein from susceptible cells by using 
monoclonal antibodies directed against the cellular binding site (Greve et al., 1989). It is an integral 
membrane protein that is a member of the immunoglobulin (Ig) superfamily of proteins and highly 
expressed on various surfaces of tissues, including the nasal epithelium, which is the entry site for 
rhinoviruses (Bella and Rossmann, 2000; Racaniello, 2007). ICAM-1 penetrates into the canyon of the 
major group viruses which encircles the fivefold axis (Olson et al., 1993). Some major group viruses 
can also use heparan sulphate as receptor (Racaniello, 2007).  
The LDLR normally mediates the transport of macromolecules into cells by receptor-mediated 
endocytosis. Differences in structure and sequence of major and minor group rhinoviruses give a hint 
why they recognize different receptors. Recent investigations have shown that minor group 
rhinoviruses contain a conserved Lys residue at position 224 of VP1 that is thought to interact with 
the negatively charged cluster of the LDLR (Vlasak et al., 2003; Verdaguer et al., 2004). Although 
several minor group rhinoviruses possess a canyon, it is thought that it is not directly involved in the 
binding of the receptor. Instead the minor group receptors bind close to the fivefold axis on the star-
shaped dome that is surrounded by the canyon (Hewat et al., 2000).  
The uncoating process probably differs for major and minor group viruses. While ICAM-1 
interactions facilitate direct RNA transfer through the membrane by initiating conformational 
changes in the capsid protein, minor group viruses are internalized into endosomes after attachment 
to the host cell. The vesicle formed proceeds to an early endosome and matures to a late endosome. 
This maturation process is associated with a decrease of the pH followed by a conformational change 
of the receptor and the virus. This leads to the release of the RNA from the viral capsid into the 
cytoplasm (Prchla et al., 1994). 
  
1.4.2 TRANSLATION AND POLYPROTEIN PROCESSING 
The plus (+) strand RNA serves as both the genome and the viral mRNA and is therefore 
infectious. Immediately after the release of the viral RNA genome into the cytoplasm of the host cell, 
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translation takes place. Most (+) strand RNA viruses do not carry a RNA dependent RNA polymerase 
with them, but encode it on their genome. Therefore viral proteins, including the viral RNA 
polymerase, have to be generated before RNA replication can take place.  
Picornaviruses do not have a cap-structure at the 5’ end and therefore require a cap-
independent mechanism to initiate synthesis of their proteins. This different mechanism of 
translation initiation to synthesize host cell proteins (cap-dependent) or viral proteins will be relevant 
for the host cell shut-off during later viral infection (see chapter 1.5). A protein is found at the 5’ end 
of picornaviruses, the VPg. This virus-encoded protein acts as a primer for transcription for positive 
and negative strand RNA synthesis and is probably not involved in translation as it was shown to be 
cleaved off before translation initiation in poliovirus (Ambros and Baltimore, 1980). 
Cap-independent translation is stimulated by the internal ribosomal entry site (IRES) which 
facilitates binding of the 40 S subunit of the ribosome (Rohll et al., 1994). Human rhinoviruses and 
enteroviruses use a type I of IRES (Borman et al., 1995). IRES structure of different type share an AUG 
codon just downstream of an oligopyrimidine tract of about 25 nucleotides (nt). However, in type I 
IRES initiation sites for polyprotein synthesis are found further downstream at about 35 nt in 
rhinoviruses (Jackson and Kaminski, 1995; Kaminsky et al., 2010). 
The 240-250 kDa long polyprotein is cleaved by viral proteases to give rise to functional 
proteins (Palmenberg, 1990). Polyprotein processing of Enteroviruses is shown in Figure 4A. 
Proteolytic processing is performed co-translationally (Toyoda et al., 1986).   
 
 
Figure 4 Cleavage events during polyprotein processing performed by picornaviral 2A
pro
 and 3C
pro
. A) After translation 
from a single open reading frame, the polyprotein is processed by viral proteases. Co-translationally, the 2A
pro
 cleaves itself 
off from the polypeptide chain, separating it into structural and non-structural proteins. This is indicated by a blue arrow. 
Most other cleavage events are performed by the 3C
pro
 and are indicated by a triangle. The final cleavage step, which takes 
place already in the newly assembled particle, is indicated by a star. The agent is unknown. Picture adapted from (Lin et al., 
2009). B) Co-translational cis cleavage event performed by the 2A
pro
 during polyprotein synthesis. The 2A
pro
 cleaves itself 
between its own N-terminus and the C-terminus of the preceding capsid protein VP1. Picture adapted from Castello et al., 
2011. 
 
In Enteroviruses, the first proteolytic cleavage event that separates the structural from the 
non-structural proteins is performed by the 2Apro in cis, implying an intramolecular reaction 
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mechanism (Figure 4B). Cleavage occurs between its own N-terminus and the C-terminus of the 
preceding protein VP1 (Toyoda et al., 1986). The 2Apro of different enteroviruses seem to recognize 
quite different cleavage sites. HRV1A 2Apro recognizes and cleaves the amino acid sequence T I T T A * 
A P S D whereas the cleavage site of HRV14 2Apro consists of the amino acid sequence D I K S Y * G L G 
P. The 2Apro is also responsible to cleave a variety of cellular proteins leading amongst others to the 
inhibition of host cell translation. 
Some picornaviruses, such as the foot-and-mouth disease virus (FMDV), use a different 
protease to initiate the first cleavage event: the leader protease or Lpro, a papain-like cysteine 
protease (Strebel and Beck, 1986). The FMDV Lpro precedes the P1 region and frees itself from the 
polyprotein by cleaving between its own C-terminus and the N-terminus of the subsequent protein 
(VP4). FMDV encodes a 2A protein, which is only 18 amino acids in length but lacks proteolytic 
activity. Nevertheless, the 2A protein frees itself from the neighboring 2B protein by a ribosomal skip 
during translation (Donnelly et al., 2001).  
The remaining cleavages to yield mature proteins are performed by the chymotrypsin-like 
cysteine protease 3Cpro (Palmenberg, 1990; Porter, 1993; Malcolm, 1995). The 3Cpro exists as a 3CDpro 
precursor, which interacts with the protease specificity to accelerate cleavage (Jore et al., 1988), but 
is also thought to act as a molecular switch that facilitates viral persistence (Buenz and Howe, 2006). 
Proteolytic cleavage of substrates by the 3Cpro or 3CDpro occurs between the amino acids Gln and Gly. 
However, it seems that Gln and Gly are not the only substrate requirements, as not all Gln*Gly 
junctions are cleaved in the PV polyprotein (Kitamura et al., 1981; Hanecak et al., 1982). Substances 
cleaved seem to have an Ala at position P4 and a Pro at position P2 of the cleavage site (Norder et al., 
2011). Enteroviral 3Cpro play also a vital role in host translation inhibition by cleaving the polyA-
binding protein (Kuyumcu-Martinez et al., 2002; Kuyumcu-Martinez et al., 2004). 
During early infection, structural proteins are cleaved into VP0 (an immature capsid precursor), 
VP3 and VP1. The final maturation step is much later in infection when the new virion particle is 
already assembled. During this final step in polyprotein processing, VP0 is cleaved into VP4 and VP2. 
The mechanism of this cleavage event remains yet to be determined (Holland and Kiehn, 1968; 
Basavappa et al., 1994).  
 
1.4.3 VIRAL REPLICATION  
A cloverleaf structure in the 5’ UTR controls the switch between translation and replication. 
The viral precursor 3CD binds to this structure and to the cellular poly-C binding protein and thereby 
represses RNA translation and enhances replication (Gamarnik & Andino 1998). 
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Efficient viral replication requires modification of cellular proteins and structures which 
induces rearrangement of intracellular membranes into characteristic vesicles. Proteins 2B and its 
precursor 2BC are thought to play a role in membrane alteration by inducing membrane 
permeabilization (Aldabe et al., 1996). Picornaviral replication occurs in such complexes associated 
with the cytoplasmic membranes and involves various picornaviral non-structural proteins, as well as 
host proteins (Bienz et al., 1992; Egger et al., 2000) .  
The major component of the replication machinery is the viral encoded RNA dependent RNA 
polymerase 3Dpol. The 3AB precursor anchors the VPg (3B) to the virally induced membranes.  A cis-
acting replication element (cre) is involved in the attachment of two uridine residues to a conserved 
Tyr region at position 3 in VPg. VPg itself acts as a primer for the RNA polymerase in positive and 
negative RNA synthesis (Cordey et al., 2008). Cis-acting elements and other structural elements help 
in recruiting the viral RNA to the replicative complex (Cameron et al., 2009).  Positive strand RNA is 
used to generate a negative strand RNA intermediate. Negative strand RNA is never found as a free 
strand but exists always as a replicative intermediate complex (positive and negative RNA) which is 
used as a template for the production of thousands of new positive strands (Crowder and Kirkegaard, 
2005). These newly synthesized positive strand RNAs can either be used for translation of viral 
proteins or for the generation of new viral RNA.  
 
1.4.4 VIRUS ASSEMBLY AND RELEASE 
In the final step of the infection cycle, when sufficient newly synthesized genomic viral RNA 
and capsid proteins have been produced, encapsidation starts. This highly specific process is 
schematically depicted in Figure 5. Only positive sense RNA which contains a VPg at its 5’ UTR is 
encapsidated (Novak and Kirkegaard, 1991). 
 
Figure 5 Assembly of the viral particle. One copy of the structural proteins VP0, VP3 and VP1 are assembled to form the 5S 
protomer. This further builds the 14S pentamer. Currently there are two mechanisms possible: RNA is internalized after the 
formation of an empty 80S capsid. Or there is a direct interaction between the 14S pentamers and the RNA leading to the 
150 provirion. The final step is the maturation cleavage of VP0 into VP4 and VP2 yielding in the mature 160S virion (Rotbart, 
1995).  
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The structural proteins are separated from the non-structural already co-translational by the 
2Apro. Cleavage by the 3Cpro leads to the capsid products VP0, VP3 and VP1. One copy of each capsid 
protein, the precursor VP0, VP3 and VP1, is assembled to form the 5S protomers. Then five 
protomers assemble to form a 14S pentamer (Palmenberg, 1982; Verlinden et al., 2000). There are 
two possible models of how assembly is performed. On suggests that, after the formation of an 
empty 80S capsid, the RNA is inserted into it (Jacobson and Baltimore, 1968).  The second model 
suggests that the 14S pentamer directly interacts with the RNA, thereby forming the 150S provirion 
with the already encapsidated RNA (Nugent and Kirkegaard, 1995). In the presence of viral RNA, the 
final step of assembly is performed, namely the cleavage of VP0 into VP2 and VP4 resulting in the 
mature 160S virion (see chapter 1.4.2). The mechanism of this proteolytic cleavage is not known. 
However, it is thought to play a role in stability of the virion and acquisition of infectivity (Basavappa 
et al., 1994). Picornaviruses are released from the cell upon cell lysis (Leong et al., 2002; Flint et al., 
2009). 
 
1.5 HOST CELL SHUT OFF 
In the early infection, viral mRNA must compete with their host counterparts for the protein 
synthesis machinery (especially for the eukaryotic translation initiation factors). During viral protein 
synthesis in an infected cell, translation of cellular proteins is subsequently shut down. Host cells 
therefore lose their ability to produce their own proteins whereas viral protein production is even 
enhanced leading to the take-over of the host cell (Etchison et al., 1982; Etchison and Fout, 1985; 
Gingras et al., 1999). The key aspect of the inhibition of host cell translation inhibition lies in the 
manipulation of the process itself, rather than in the disruption of cellular mRNA.  
The 7-methyl-guanosine capped structure at the 5’ end of eukaryotic mRNA is an important 
feature in cellular translation. This cap structure is important to initiate translation as it recruits the 
so called 43S pre-initiation complex (containing the 40S ribosomal subunit, the ternary complex Met-
tRNA and eIF2-GTP) to the mRNA. This recruitment involves several eukaryotic translation initiation 
factors (eIFs). The cap-binding protein or eIF4E recognizes and binds the 5’ cap structure on the 
mRNA (Sonenberg et al., 1978; Svitkin et al., 2005).  Additionally, it also binds the N-terminal domain 
of eIF4G which itself acts as central scaffold protein for the initiation complex. The other C-terminal 
domain of eIF4G binds eIF4A and eIF3. The polyA-binding protein (PABP) which attaches to the poly-
A tail on the 3’ UTR is also linked to the eIF4G leading to a circularization of the complex (Imataka et 
al., 1998). After the assembly of this eIF4F complex (eIF4A, 4G and 4E), the 43S pre-initiation complex 
binds and scans along the 5’ UTR until an AUG initiation codon is encountered, which leads to an 
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abrogation of the scanning and to hydrolysis of the bound GTP of eIF2. Thereby, the pre-initiation 
factors dissociated from the small subunit and the large ribosomal subunit is bound leading to the 
start of protein synthesis (Pain, 1996; Borman et al., 1997). Figure 6A shows a schematic 
representation of the cap-dependent translation initiation complex.  
 
 
Figure 6 Cap-dependent and cap-independent translation initiation. A) Intact eIF4G is the scaffold protein which brings the 
43S subunit to the cellular mRNA. In the course of viral infection, eIF4G is cleaved by the 2A
pro
 in HRVs leading to the 
abrogation of cellular protein synthesis and enhancement of cap-independent translation. Binding of polyA tail by the PABP 
leads to a circularization. B) Viral translation is not effected as it is not cap-dependent, but viral mRNA contains an IRES 
structure important for translation initiation (Flint et al., 2009). 
 
During picornaviral infection, the scaffold protein eIF4G is cleaved by virally encoded proteases 
(enteroviral 2Apro or FMDV Lpro) inhibiting the binding of the ribosome to cellular mRNA. 
Picornaviruses translate their proteins in a cap-independent way via an IRES structure present in the 
5’ UTR of the viral genome. This IRES structure facilitates ribosomal recruitment and requires also 
almost all cellular eukaryotic initiation factors used in cap-dependent translation. However, after the 
cleavage of eIF4G enteroviral protein synthesis works even more efficiently than in presence of intact 
eIF4G (Borman and Kean, 1997). Figure 6B shows a schematic representation of enteroviral 
translation via an IRES structure.  
In HRV, the enzyme responsible for this host cell shut off is the 2Apro in HRV, which is able to 
cleave eIF4G directly (Figure 7). There are two homologues of eIF4G present in eukaryotic cells, eIF4G 
I and II (Gradi et al., 1998; Lloyd, 2006). Gradi et al. have shown that both types of eIF4G have to be 
cleaved to lead to host-cell shut off. It has been shown that HRV2 2Apro cleaves the sites L S T R * G P 
P R on eIF4GI (Lamphear et al., 1993) and L L N V * G S R R at eIF4GII (Gradi et al., 2003). However, by 
site directed mutagenesis, it was also shown that the binding and cleavage sites on eIF4GI differ. In 
these experiments, the 2Apro is able to bind eIF4GI fragments which lack the cleavage site amino 
acids Arg*Gly in eIF4GI and are therefore not able to perform cleavage (Foeger et al., 2000; Foeger et 
al., 2002). 
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Figure 7 Overview of the eIF4G scaffold protein and 2A
pro
 cleavage site. 2A
pro
 of HRV cleaves eIF4G I and II during 
infection. Arrows indicated cleavage sites in eIF4G I and II for enteroviral 2A
pro
. eIF4G binding domains for PABP, eIF4E, eIF3 
and eIF4A and Mnk are shown as well. Picture from (Flint et al., 2009). 
 
1.6 2A PROTEINASE (2APRO) 
1.6.1 FUNCTION 
In Enteroviruses, the 2Apro is essential for viral translation as it separates the structural from 
the non-structural proteins by cleaving the polyprotein (Toyoda et al., 1986). The 2Apro cleaves 
between its own N-terminus and the C-terminus of the preceding protein VP1. This initial cleavage 
event is performed co-translationally and only in cis, implying an intramolecular reaction mechanism. 
As mentioned in chapter 1.5, it also plays a very important role during host cell shut-off as it cleaves 
the two homologues of eIF4G leading to an abrogation of cellular protein synthesis. In addition, 2Apro 
of different picornaviruses cleave several other cellular proteins, such as the polyA-binding protein 
PABP, which was shown to be cleaved by PV 2Apro and 3Cpro (Joachims et al., 1999) and CV B3 2Apro 
(Kerekatte et al., 1999), dystrophin, which was shown to be cleaved by the CVB3 2Apro (Badorff et al., 
1999) and cytokeratin 8, which was shown to be cleaved by the 2Apro of HRV2 (Seipelt et al., 2000). 
The 2Apro of HRV2 also alters RNA and protein trafficking between the nucleus and the cytoplasm by 
proteolysis of several nucleoporins (Gustin and Sarnow, 2001; Park et al., 2008; Park et al., 2010). 
Table 1 summarizes this data. 
Protein Cleaved by  
PolyA Binding Protein PV 2Apro and 3Cpro CV-B3 2Apro 
Dystrophin CV-B3 2Apro 
Cytokeratin 8 HRV 2Apro, CV-B4 2Apro 
Nup 62 HRV 2Apro 
Nup 98 HRV 2Apro 
Nup 153 HRV 2Apro 
Table 1 Cellular proteins cleaved by enteroviral 2A
pro
. 
 
                                                                                                                             
25 
Crowder and Kirkegaard showed that PV bearing a mutation that makes the 2Apro enzyme 
inactive can also act as a dominant negative inhibitor of wild-type growth (Crowder and Kirkegaard, 
2005). Co-infection of cells with wt PV and PV containing a mutation in the 2Apro that inhibits 2Apro 
activity showed that intracellular growth was inhibited also for the wt virus. As the cleavage between 
VP1 and 2Apro is exclusively intramolecular (Toyoda et al., 1986), and therefore wild type structural 
products are produced, it was postulated that uncleaved VP1-2Apro can assembly with wild type VP0 
and VP3 to form non-functional capsids, and thereby preventing viral growth (Crowder and 
Kirkegaard, 2005). 
 
1.6.2 STRUCTURE  
The enteroviral 2Apro is a protein composed of 142 – 149 amino acids that belong to the 
cysteine protease group (Konig and Rosenwirth, 1988) with a chymotrypsin-like fold (Bazan and 
Fletterick, 1988). At the moment, two structures of 2Apro are available: the crystal structure from 
HRV2 (Petersen et al., 1999) and the NMR structure from coxsackievirus B4 (Baxter et al., 2006). In 
Figure 8, the crystal structure of HRV2 2Apro is shown.  
 
Figure 8 Structure of HRV2 2A
pro
. The catalytic triad residues His18, Asp35 and Cys106 are shown in red. The residues 
Cys52, Cys54, Cys112 and His114 that coordinate the zinc ion (black) are shown in yellow. The β-strands are highlighted in 
dark blue, α-helices in light blue and loops in violet. Created with Pymol (DeLano, 2002) using the PDB ID code 2HRV2. 
 
In comparison to chymotrypsin, a prototypic serine proteinase, the 2Apro exhibits some unique 
characteristics in its structure. Instead of a serine as the active site nucleophile, it contains a cysteine. 
As in chymotrypsin, the 2Apro contains a N-terminal and a C-terminal domain which is connected by 
an interdomain loop. However, the N-terminal domain is made up of four β-strands forming an 
antiparallel β-sheet, whereas the N-terminus of chymotrypsin is built from 8 β-strands. The C-
 
26 
terminus of the 2Apro is made of 6 β-strands forming a β-barrel. For the formation of an active 
enzyme, a zinc ion coordinated by Cys52, Cys54, Cys112 (via sulfur) and His114 (via nitrogen) was 
shown to be required. This tightly bound zinc ion is thought to be essential for the stability of the 
protein, presumably by compensating the truncation of the N-terminal domain (Sommergruber et al., 
1994; Voss et al., 1995; Petersen et al., 1999). However, it seems not to be involved in functionality 
of the 2Apro, as it rather far away from the active site (> 20 Å) and not accessible to other ligands.   
The catalytic triad which is located at the junction of the N- and C-terminal domains  is formed 
by the nucleophile Cys106, the general base His18 and Asp35 as determined by mutational analysis 
and confirmed by the crystal structure (Yu and Lloyd, 1991; Sommergruber et al., 1997; Petersen et 
al., 1999). Figure 9A shows the catalytic triad. Although actives site residues in other chymotrypsin-
related serine proteinases are normally rather rigid, His18 shows an unusual flexibility. This structure 
is stabilized by Asp35. Asp35 itself is fixed by a well-established hydrogen bonding network involving 
several other residues.  
 
 
 
Figure 9 Important hydrogen bonding networks stabilizing the active site of HRV2 2A
pro
. A) Active site residues His 18, 
Asp35 and Cys106 are shown. Asp35 is part of a hydrogen bonding network stabilizing itself and the rather unusual flexible 
His18. B) Oxyanion hole stabilizing the negative charge in the substrate binding site. Created with Pymol (DeLano, 2002) 
using the PDB ID code 2HRV2. 
 
Cleavage of the peptide bond is a two-step reaction. In the first step, a covalent bond between 
the C1-atom of the substrate (at position P1) and the sulfhydryl group of the reactive Cys residue of 
the enzyme is formed. The His provides a general base and accepts a proton from the sulfhydryl 
group of the reactive Cys, which leads to the formation of an intermediate. During the formation of 
this intermediate, a negative transition state intermediate is formed where the bonds of the C1 of 
the substrate have tetrahedral geometry in contrast to the planar triangular geometry in the peptide 
group. A structure called the “oxyanion hole”, which is part of the enzyme, stabilizes the negative 
charge of the oxygen atom attached to the C1-atom (at position P1). Stabilization is achieved by a 
hydrogen bonding network formed by Asp105 with various residues and is shown in Figure 9B. After 
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the breakage of the peptide bond, one cleavage product is released, whereas the second is still 
attached to the enzyme. This product-enzyme is then hydrolyzed by a water molecule to release the 
second cleavage product and the enzyme. This process again proceeds through a negative 
tetrahedral transition state (Branden and Tooze, 1999; Sarkany et al., 2000). 
 
1.6.3 SUBSTRATE SPECIFICITY 
Most experiments made on the substrate specificity of 2Apro have been done on PV-1 (Hellen 
et al., 1992) and HRV2 (Sommergruber et al., 1992; Petersen et al., 1999). As HRV1A belongs to the 
same group as HRV2 and the cleavage sites of HRV2 and HRV1A 2Apro are rather similar, the substrate 
specificity of HRV2 is discussed here.  
The 2Apro cleavage site for self-processing reactions, consisting of 5 residues of the C-terminal 
part of VP1 (also designated as P site) and 4 residues of the N-terminal part of the 2Apro (also 
designated as P’ site), is recognized by the 2Apro and cleaved. The nomenclature of Schechter and 
Berger was used to describe the residues of the cleavage site (Schechter and Berger, 1967). In Figure 
10 and 11, a substrate was modeled into the binding cleft of HRV2 2Apro. For substrate recognition, 
residues at position P1’, P2 and P4 seem of great importance. Indeed, the only absolutely conserved 
residue in the cleavage site of 2Apro is the Gly at position P1’ indicating the strong requirement for 
this residue. The presence of Glu, Lys, Thr and Trp at this site were shown to inhibit the self-cleavage 
reaction (Skern et al., 1991). Petersen et al. (Petersen et al., 1999)  explain the absolute requirement 
of Gly at P1’ to be due to Leu19 that blocks the access of any residues other than Gly to the S1’ site.  
 
Figure 10 Model of substrate binding in HRV2 2A
pro
. A peptide (P4-P1’) was modeled into the binding cleft of the HRV2 
2A
pro 
structure.  The important hydrogen bond of Ser83 with Thr at position P2 is shown and Tyr85 has been rotated out in 
order to form an S2 site. Created with Pymol (DeLano, 2002) as described by Petersen et al., 1999. A brief description of 
how this model was generated is given in chapter 5.2.   
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At P2, a Thr is found in HRV2 (and HRV1A). However, binding of a substrate with a Thr residue 
at P2 requires a rotation of Tyr85 away from its original position, stacked upon His18, so that Thr at 
P2 can form a hydrogen bond with Ser83. This hydrogen bond seems to compensate for this rotation 
(Petersen et al., 1999). Peptides with a Val at position P2 are not cleaved due to the inability to form 
a hydrogen bond. However, HRV2 2Apro does process Thr, Asn, Ser at the P2 position of the cleavage 
site. By exchanging the P2 position of HRV14, which originally contains a Ser, with Thr, a 5-fold more 
efficient cleavage of oligopeptides by the HRV14 2Apro can be observed (Sommergruber et al., 1992).  
Hydrophobic residues such as Leu or Ile are found at the P4 site due to their flexibility of the 
side chains as the S4 site is a rather narrow but deep pocket (Petersen et al., 1999).  
The other positions of the substrate binding site can be rather diverse. For instance, the 
cleavage site of wild type HRV2 2Apro contains an Ala at P1 position. However, it accepts a variety of 
amino acids such as Met, Leu, Tyr, Phe, Thr, and Arg as well and even shows higher cleavage 
efficiency with Met or Tyr at this site. This can be explained by the narrow and flat character of the 
S1 pocket formed by the eII strand and the oxyanion hole and is mainly filled by the side chains of 
Cys101 and Glu102 at the bottom of the pocked providing a negative charge. Residues with long and 
flexible side chains, such as Met, can fit in the S1 site more easily, as well as residues with positive 
side chains, as Arg and Lys. Negative charged substrates containing Asp and Glu were not cleaved at 
all (Skern et al., 1991; Sommergruber et al., 1992). P2’ can also accept several other amino acids such 
as Phe, Thr, Asn and Lys, however, compared to wild type cleavage of HRV2 with Pro at position P2’, 
cleavage was reduced to about two to five folds (Sommergruber et al., 1992).   
 
Figure 11 Surface model of the substrate binding cleft of HRV2 2A
pro
. The narrow and flat S1 pocket formed by Cys101 and 
Glu102 is shown. Residues 82-89 from the dityrosine flap have been removed. Picture taken from (Petersen et al., 1999).  
 
The specificity of the HRV1A and HRV14 2Apro appear to be different. Figure 12 shows the 
cleavage sites for different enteroviral 2Apro enzymes. These cleavage sites have only a few residues 
in common, as only residues at position P4, P2 and P1’ are identical.  
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Figure 12 Comparison of the 2Apro cleavage sites of different picornaviruses. Sequence alignment of selected 
picornaviruses: HRV human rhinovirus, CV coxsackievirus, EV enterovirus, PV poliovirus; The P site represents the                  
C-terminus of VP1 and the P’ site the N-terminus of 2A
pro
. Numbers indicate the position of amino acid residues relative to 
the scissile bond between the VP1 and the 2A
pro
, which is indicated by an asterisk. The sequences have been taken from the 
database www.ncbi.nlm.nih.gov. Sequence IDs: AY458604 (HRV-A 1a), Xo2316.1 (HRV-A 2), X01087 (HRV-B 14), EF582387.1 
(HRV-C 026) ABV60422 (PV 1), DQ480420 (CV-B 4), U22521.1 (EV 71). Sequence alignment was made online using ClustalW 
(http://www.ebi.ac.uk/Tools/ msa/clustalw2/) and edited with the programme BioEdit. 
 
For this work the difference in cleavage site residues of HRV1A 2Apro and HRV14 2Apro is the 
most important. Identical residues are the Ile at position P4 and the Gly at position P1’. Similar 
residues are located at position P2 (Thr, Ser in HRV1A, HRV14 respectively). Thr and Ser are both able 
to make hydrogen bonds, and are maybe involved in forming a hydrogen bond with Ser83 as it was 
shown in HRV2 (see chapter 1.6.3). In contrast, different residues are found at position P5, P1, P2’ 
and P4’. Wang et al. showed that HRV14 2Apro cleaves poorly a peptide with its wild type cleavage 
site poorly in vitro and showed that when HRV14 residue Leu at position P2’ was mutated to Pro (as 
in HRV1A) or Ser at position P2 was mutated to Thr resulted in a 12 fold higher cleavage efficiency 
than with the wild type residues (Wang et al., 1998).  
The cleavage site on eIF4G recognized by the 2Apro contains T L S T R * G P P R (Lamphear et al., 
1993). It shows a similar substrate binding motif: a hydrophobic amino acid at P4, Thr at P2 and Gly 
at P1’. Although eIF4G is cleaved directly by the 2Apro, its cleavage efficiency in vitro is not very high, 
but is significantly improved when it is part of the eIF4F complex (Haghighat et al., 1996). This 
suggests that after binding of eIF4E to eIF4G, there is a change in conformation of eIF4G in 
narrowness allowing a better binding and cleavage of the 2Apro (Petersen et al., 1999). 
Sousa et al. showed that HRV14 2Apro was not able to carry out self-processing when the wt 
cleavage site was replaced by that of eIF4GI. In contrast to that HRV2 2Apro is able to perform self-
processing. Site-directed mutagenesis showed that the Arg at position P1 was responsible for the 
cleavage inhibition of HRV14 2Apro. This result indicated that HRV14 2Apro might cleave at a different 
site on eIF4G than HRV2. By solely replacing the Tyr at position P1 with an Arg cleavage of HRV14 
2Apro was also inhibited (Sousa et al., 2006).  
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2 AIM OF THE WORK 
This thesis focuses on the substrate specificity of the 2Apro of HRV1A and HRV14. 
Understanding protease substrate specificities is of crucial importance in developing antiviral 
inhibitors specifically targeting the 2Apro, a highly conserved protease in Enteroviruses.  
During the course of this work, the first cleavage reaction in picornaviruses, which is executed 
by the 2Apro, is monitored by using an in vitro system employing rabbit reticulocyte lysates (RRL). This 
in vitro system is used to investigate the intramolecular cleavage between the C-terminus of the 
preceding protein VP1 and its own N-terminus. Although a crystal structure of HRV2 2Apro is available, 
we performed our experiments with HRV1A, another group A human rhinovirus, as the transfection 
efficiency of HRV2 RNA in HeLa cells is very low compared to that in HRV1A RNA. A high transfection 
efficiency is necessary for our experiments in order to be able to isolate compensatory mutants later.   
Which are the crucial residues of 2Apro required to recognize the substrate at the VP1-2Apro 
junction? Although this cis cleavage is a highly conserved, co-translational process in different 
Enteroviruses, the residues in the cleavage site are rather diverse. Several studies have been 
performed to identify important residues in the 2Apro cleavage sites (Skern et al., 1991; 
Sommergruber et al., 1992). During the course of this work, we aimed to exchange residues at the 
VP1-2Apro junction of HRV1A with those from HRV14 in order to identify which residues in the 
cleavage junctions are not accepted by the 2Apro and which are exclusively required to carry out this 
important self-cleavage process. Subsequently, cleavage site residues identified as being sub-optimal 
for this cleavage were to be introduced into a HRV1A full length clone in order to be able to transfect 
HeLa cells with viral RNA containing the desired mutations. From the viral offspring, we will try to 
isolate virus with second site revertants. This should help us to identify structurally important amino 
acids in various positions of the 2Apro enzyme or cleavage site. We further tried to determine why 
glycine at position P1’ is absolutely required for performing this cis-cleavage event.  
Is the activity of the 2Apro influenced by the sequence of the neighboring proteins? In another 
set of experiments, the protease activity of the HRV14 2Apro was to be monitored. The influence of 
mutations in the protein VP1 (Y289R) and in the 2B (I94N) was to be investigated as both mutations 
had been shown to prevent the 2Apro from performing self-processing (Sousa et al., 2006; Neubauer 
et al., 2009) Again, viral RNA carrying the desired mutations was transfected into HeLa cells and we 
tried to isolate second site revertants that might have recovered the biological activity of the 2Apro. 
We hypothesize that such mutations identified could shed light on the specificity and mechanism of 
the 2Apro.  
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3 MATERIALS AND METHODS 
 
3.1 PLASMIDS AND CONSTRUCTS 
For in vitro experiments the pCITE vector (Novagen), containing a cap-independent translation 
enhancer (CITE) sequence, that derived from the encephalomyocarditis virus (EMCV) and facilitates 
internal initiation of protein synthesis was used. This vector also contains a T7 promoter before the 
CITE that allows in vitro transcription by T7 RNA polymerase. The pCITE vector containing the HRV2 
VP1-2Apro, containing a NcoI and BamHI restriction site before and after the coding sequence of the 
viral proteins, was kindly provided by David Neubauer.  The HRV2 VP1-2Apro was exchanged by 
HRV1A cDNA encoding the VP1-2Apro (Figure 13A). Therefore NcoI and BamHI restriction sites were 
introduced before and after the cDNA of HRV1A VP1-2Apro via standard PCR and used to exchange 
the HRV2 VP1-2Apro with the corresponding fragment of HRV1A VP1-2Apro. All plasmids used 
throughout the experiments code for a gene that gives resistance to ampicillin, which was used to 
screen for bacterial clones that carried the plasmid. 
 
 
Figure 13 HRV1A plasmids used without modifications. A) pCITE HRV1A VP1-2A
pro
. B) pHRV1A containing the full HRV1A 
genome. Single restriction sites available are shown. Pictures made with CloneManager. 
 
 
The HRV1A VP1-2Apro was used for monitoring wild type HRV1A cleavage of the 2Apro. Further 
on cleavage site residues of the HRV1A 2Apro were exchanged by introducing the restriction sites 
BsiWI and BstEII via silent mutations around the cleavage junction of the 2Apro (55 bp apart from each 
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other) by standard PCR. Phosphorylated primer containing mutated residues were used to modify 
the cleavage site via cassette cloning. Prior to in vitro transcription plasmids were linearized with 
BamHI.  
For transfection experiments in HeLa cells full length HRV1A mRNA was used (Figure 13B). The 
plasmid pHRV1A, containing the cDNA of the complete HRV1A genome was kindly provided by 
McKnight. Unfortunately no whole sequence map was available, but the plasmid was sequenced on 
both sides, upstream and downstream from the coding sequence. Sequence results showed that the 
plasmid belongs to the family of pGEM vectors – probably pGEM13-Zf(+). The plasmid pHRV1A is 
10125 bp in size and also contains a T7 promoter, an IRES and a gene coding for ampicillin resistance. 
BsiWI and BstEII restriction sites were introduced around the cleavage junction of the 2Apro via PCR 
mutagenesis and the cleavage site was again modified by introducing phosphorylated primers 
containing mutated residues via cassette cloning. Prior to in vitro transcription the plasmid was 
linearized with MluI.  
In vivo experiments with HRV14 were performed with a plasmid containing full length HRV14 
cDNA (Figure 14). This pHRV14 as3f contained either a mutation in the VP1 protein (Y289R) or in the 
2B protein (I94N), which were both thankfully provided by David Neubauer. 
  
Figure 14 HRV14 plasmid used without modifications. Single restriction sites available are shown. Picture made with 
CloneManager. 
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3.2 OLIGONUCLEOTIDES 
Oligonucleotides were purchased from Eurofin MWG Operon.  
 
 PRIMERS USED FOR SITE DIRECTED PCR MUTAGENESIS  3.2.1
Table 2 Oligonucleotides used for site directed PCR mutagenesis. Restriction sites are shown underlined..   
 
 
 OLIGONUCLEOTIDES FOR CASSETTE CLONING 3.2.2
Primer Sequence (orientation 5` to 3`) Description 
Tim 1849 5’ CCACAACCATGGTAGAAAACTACATTGATGAAG 3’ Sense primer for the introduction of a NcoI restriction site 
into pCITE HRV1A VP1-2A
pro 
Tim 1850 5’CCCGGGGGATCCTTATCATTGTTCCTCAGCACAGTGA
AATTG 3’ 
Antisense primer for the introduction of a BamHI 
restriction site into pCITE HRV1A VP1-2A
pro
 
Tim 1851 5’CGTGACAACAGCCATCGTACGCAGAAACACTATAACA
ACTG 3’ 
Sense primer for the introduction of a BsiWI restriction 
site (silent mutation) into pCITE HRV1A VP1-2A
pro
 and into 
pHRV1A full length clone 
Tim 1852 5’CAGTTGTTATAGTGTTTCTGCGTACGATGGCTGTTGTC
ACG 3’ 
Antisense primer for the introduction of a BsiWI restriction 
site (silent mutation) into pCITE HRV1A VP1-2A
pro
 and into 
pHRV1A full length clone 
Tim 1853 5’CTATATGTGCATGTAGGTAACCTAATATATAGAAACTT
ACATCTG 3’ 
Sense primer for the introduction of a BstEII restriction 
site (silent mutation) into pCITE HRV1A VP1-2A
pro
 and into 
pHRV1A full length clone 
Tim 1854 5’CAGATGTAAGTTTCTATATATTAGGTTACCTACATGCA
CATATAG 3’ 
Antisense primer for the introduction of a BstEII restriction 
site (silent mutation) into pCITE HRV1A VP1-2A
pro
 and into 
pHRV1A full length clone 
Tim 1887 5’ GTGTTTTGTTTCTGCATGTAAAG 3’ Sense primer for the introduction of BsiWI/ BstEII 
restriction site (silent mutation) into the pHRV1A full 
length clone  
Tim 1888 5’ ATGTAACACTTGAAACCATTTGG 3’ Antisense primer for the introduction of BsiWI/ BstEII 
restriction site (silent mutation) into the pHRV1A full 
length clone 
Primer Sequence (orientation 5` to 3`) Description 
Tim 1859 5’GTACGCAGAAACGATATCAAATCCTATGGTTTAGGAC
CTCTATATGTGCATGTAG 3’ 
Introduction of the cleavage site DIKSY*GLGP into pCITE 
HRV1A VP1-2A
pro
 and pHRV1A full length clone (silent 
mutation: EcoRV) Tim 1860 
5’GTTACCTACATGCACATATAGAGGTCCTAAACCATAGG
ATTTGATATCGTTTCTGC 3’ 
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Table 3 Oligonucleotides used for cassette cloning. Cleavage sites are shown underlined. 
 
 PRIMERS USED FOR SEQUENCING 3.2.3
 
 PRIMERS USED FOR RT-PCR OF VIRAL RNA 3.2.4
Primer Sequence (orientation 5` to 3`) Description 
Tim 1795 5’ GGCAAAGTGCTTCAAACC 3’ Sense primer for PCR amplification of cDNA of HRV14 plaques 
Tim 1796 5’ GCCATTGGAGGCAAGAAATC 3’ Antisense primer for PCR amplification of cDNA of HRV14 plaques 
Tim 1915 5’ TTTTATGATGGATATGATGG 3’ Sense primer for PCR amplification of cDNA of HRV1A plaques 
Tim 1921 5’ GTAACACTTGAAACCATTTGG 3’ Antisense primer for PCR amplification of cDNA of HRV1A plaques 
 
Table 5 Oligonucleotides used to reverse transcribe and amplify viral mRNA isolated from plaques. 
Tim 1861 5’GTACGCAGAAACGATATCAAATCCTATGGGCCCAGTG
ATCTATATGTGCATGTAG 3’ 
Introduction of the cleavage site DIKSY*GPSD into pCITE 
HRV1A VP1-2A
pro
 and pHRV1A full length clone (silent 
mutation: EcoRV) Tim 1862 
5’GTTACCTACATGCACATATAGATCACTGGGCCCATAGG
ATTTGATATCGTTTCTGC 3’ 
Tim 1863 5’GTACGCAGAAACACTATAACAACAGCTGGTTTAGGAC
CTCTATATGTGCATGTAG 3’ 
Introduction of the cleavage site TITTA*GLGP into pCITE 
HRV1A VP1-2A
pro
 and pHRV1A full length clone (silent 
mutation: PvuII) Tim 1864 
5’GTTACCTACATGCACATATAGAGGTCCTAAACCAGCTG
TTGTTATAGTGTTTCTGC 3’ 
Tim 1867 5’GTACGCAGAAACACTATAAAATCCTATGGCCTAAGCG
ATCTATATGTGCATGTAG 3’ 
Introduction of the cleavage site TIKSY*GLGP into pCITE 
HRV1A VP1-2A
pro
 and pHRV1A full length clone (silent 
mutation: Bpu10I) Tim 1868 
5’GTTACCTACATGCACATATAGATCGCTTAGGCCATAGG
ATTTTATAGTGTTTCTGC 3’ 
Tim 1869 5’GTACGCAGAAACACTATAACATCCTATGGCCTAAGCG
ATCTATATGTGCATGTAG 3’ 
Introduction of the cleavage site TITSY*GLGP into pCITE 
HRV1A VP1-2A
pro
 and pHRV1A full length clone (silent 
mutation: Bpu10I) Tim 1870 
5’GTTACCTACATGCACATATAGATCGCTTAGGCCATAGG
ATGTTATAGTGTTTCTGC 3’ 
Tim 1871 5’GTACGCAGAAACACTATAACAACAGCTGCACCCAGTG
ATCTATATGTGCATGTAG 3’ 
Introduction of the cleavage site TITTA*APSD into pCITE 
HRV1A VP1-2A
pro
 and pHRV1A full length clone (silent 
mutation: PvuII) Tim 1872 
5’GTTACCTACATGCACATATAGATCACTGGGTGCAGCTG
TTGTTATAGTGTTTCTGC 3’ 
Primer Sequence (orientation 5` to 3`) Description 
Tim 1797 5’ GCACTACCCTACACATCAATAGG 3’ Sense primer for sequencing of cDNA from HRV14 plaques 
Tim 1798 5’ CCTGTGTTGGATTCGAGATATGC 3’ Antisense primer for sequencing of cDNA from HRV14 plaques 
Tim 1922 5’ CCCTTACACACATAGTCATGTG 3’ Sense primer for sequencing of cDNA from HRV1A plaques 
Tim 1923 5’ ATTTCACATTTGATTTTCTCTTG 3’ Antisense primer for sequencing of cDNA from HRV1A plaques 
Tim 1928 5’ ATCCATTCAAGACCACGTGCAG 3‘  Antisense primer for sequencing of 2B of cDNA from HRV1A plaques 
Table 4 Oligonucleotides used for sequencing. 
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3.3 DNA METHODS 
 AMPLIFICATION OF DNA FRAGMENTS BY PCR (POLYMERASE CHAIN 3.3.1
REACTION) 
3.3.1.1 Introduction of mutations by site directed PCR mutagenesis 
For the introduction of mutations of one or a few base pairs into plasmid DNA, complementary 
primers containing the mismatches were designed. To ensure proper hybridization to the template, 
regions of exact homology to the template were included on both sides around the mutated site.  
 A standard PCR reaction of 50 µl consists of:  
   0.5 µl  DNA 
   1.0 µl  Sense primer (1 µg/µl) 
   1.0 µl  Antisense primer (1 µg/µl) 
   2.5 µl  dNTPs (2.5 mM) (Invitrogen) 
   5.0 µl  10x Pfu Buffer (Promega) 
   1.0 µl  Pfu Polymerase (3 u/µl) (Promega) 
39.0 µl  dH2O 
50.0 µl 
PCR was performed on a Perkin Elmer DNA Thermal Cycler 480 with the following conditions:  
Temperature [°C] Time [min] Step 
95 °C 2 minutes 1.Initial denaturation  
95°C 
 x °C 
72°C 
1 minute 
1 minute 
4-20 minutes 
2. Denaturation  
3. Annealing 
4. Extension 
72°C 5 minutes 5. Final extension  
4°C   6. Storage 
Table 6 PCR reaction conditions, steps 2-4 were repeated 30 times. Annealing temperature (x) depends on the melting 
temperature of the primers. Usually annealing temperatures were 5-10°C lower than the calculated melting temperature of 
the primers. Extension time depends on the length of the DNA template. Normally per 1000 bp of sequence length two 
minutes are needed for extension.  
 
Template DNA in the PCR mix contains methylated adenines, which allow digestion with DpnI.  
10 µl of the PCR reaction were kept as undigested control, whereas the remaining part was digested 
with 1 µl DpnI (New England Biolabs, 20 u/µl) and 4.5 µl NE Buffer 4 for 5 h at 37°C. 10 µl of the 
template-free PCR reaction and 10 µl of the undigested control were analyzed on a 1% agarose gel 
(see chapter 3.3.6.1). For the transformation in competent E. coli Top 10 cells 10 µl of digested DNA 
was used (see chapter 3.3.3).  
 
30 cycles 
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3.3.1.2 Manipulation of cleavage sites by cassette cloning 
For replacing a small DNA fragment (up to 50 nucleotides) at the cleavage site of the 2Apro with 
a new fragment, bearing the desired mutations, cassette cloning was applied.  Two primers 
complementary to each other, containing the desired mutations and the same restriction sites 
(correct sticky ends) used to digest the vector, were phosphorylated on the 5’ end (see chapter 
3.3.7.3) and ligated into a digested and dephosphorylated vector (see chapter 3.3.7.1, 3.3.7.2 and 
3.3.7.4).  The plasmid bearing the desired mutation was then transformed into E.coli Top10 cells (see 
chapter 3.3.3).  
  
3.3.1.3 Generation of cDNA by RT- PCR 
The process of RT-PCR (reverse transcription – polymerase chain reaction) was carried out in 
two separate steps; the initial production of cDNA from the isolated RNA using SuperScript® III 
Reverse Transcriptase (Invitrogen, 200 u/µl), and the subsequent amplification of the synthesized 
cDNA by PCR. Mutant viruses were isolated by picking plaques from cell culture plates. After three 
rounds of plaque purification, viral RNA was resuspended in 100 µl PBS, freeze/thawed three times 
and centrifuged at 6500 rpm for 5 minutes, separating the virus (in the supernatant) from dead cells.  
First strand cDNA synthesis is performed in a total volume of 20 µl composed of:  
 11 µl Virus supernatant     
  2 µl  1 µM antisense primer 
   1 µl 2.5 mM dNTPs (Invitrogen) 
   2 µl  10x first strand buffer 
   1 µl  RNasin® RNase Inhibitor (Promega, 40 u/µl) 
   1 µl  SuperScript® III Reverse Transcriptase (Invitrogen, 200 u/µl) 
   2 µl  dH2O 
 20 µl 
 
Negative controls with in vitro transcribed RNA with or without SuperScript® III Reverse 
Transcriptase were performed as well. Synthesis of cDNA from an RNA template was performed on a 
Perkin Elmer DNA Thermal Cycler 480 with the following conditions:  
Temperature [°C] Time [min] Step 
55 °C 10 minutes  
40°C 60 minute Reverse Transcription  
70°C 15 minutes Inactivation of RT  
Table 7 Conditions for reverse transcription reaction. 
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The created cDNA can then be used as template for amplification in PCR:  
  2.5 µl  cDNA (from first-strand reaction) 
   1.0 µl  Sense primer (1 µg/µl) 
   1.0 µl  Antisense primer (1 µg/µl) 
   2.5 µl  dNTPs (2.5 mM) (Invitrogen) 
   5.0 µl  10x Pfu Buffer (Promega) 
   1.0 µl  Pfu Polymerase (3 u/µl) (Promega) 
37.0 µl  dH2O 
50.0 µl 
 
PCR was performed on a Perkin Elmer DNA Thermal Cycler 480 with the following conditions:  
Temperature [°C] Time [min] Step 
95 °C 2 minutes 1.Initial denaturation  
95°C 
37 °C 
72°C 
1 minute 
1 minute 
4 minutes 
2. Denaturation  
3. Annealing 
4. Extension 
72°C 5 minutes 5. Final extension  
4°C   6. Storage 
 
 
Table 8 PCR reaction conditions for amplification of cDNA after reverse transcriptase. Steps 2-4 were repeated 30 times.  
 
 
The synthesized cDNA was checked on an agarose gel (see chapter 3.3.6.1), concentration was 
determined using the NanoDrop (see chapter 3.3.10) before sending it for sequencing (see chapter 
3.3.11).   
 
 PREPARATION OF CHEMICALLY COMPETENT CELLS  3.3.2
A 3 ml overnight culture of competent E.coli TOP10 cells was grown in 2x TY medium overnight 
at 37°C with rotation at 220 rpm. On the following day 100 ml of 2x TY medium was inoculated with 
the overnight culture and grown at 37°C for 2-3 hours until an OD600 of 0.45-0.55 was reached. Cells 
were then incubated on ice for 15 minutes, before centrifuging them for 15 minutes at 2500 rpm at 
4°C. The pellet was resuspended in 33 ml RF1 suspension and incubated for 15 minutes on ice and 
centrifuged as described before. The pellet was taken up in 8 ml RF2 suspension and the bacterial 
solution was then divided in 200 µl aliquots, snap frozen in liquid nitrogen and stored at -80°C.  
 
 
30 cycles 
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Solutions: 
2x TY medium (1l)  RF1 solutions  RF2 solution 
16 g Tryptone 
10 g Yeast extract 
5 g NaCl  
Adjusted with NaOH to a     
pH 7 
 100 mM KCl 
100 mM MnCl2 
30 mM K-Acetate 
10 mM CaCl2 
15% (w/v) Glycerol 
Adjusted with HCl to a pH 5.8  
 10 mM MOPS 
10 mM KCl 
75 mM CaCl2 
15% (w/v) Glycerol  
Adjusted with KOH to a pH of 
6.08  
 
 BACTERIAL TRANSFORMATION BY HEAT SHOCK 3.3.3
Throughout all cloning experiments E.coli TOP10 bacterial cells were used to amplify plasmids 
in order to make larger quantities of it.  
In order to make the bacterial cells “competent” to take up DNA, the procedure of heat shock 
is applied. Bacterial cells, which were suspended in a solution containing high concentration of 
calcium, were thawed on ice and DNA (0.1 µl of plasmid DNA or 10 µl of a ligation) was added. Cells 
and DNA were together incubated on ice for 15°C, placed at 42°C (heat shock) for 50 seconds and put 
back on ice briefly. 400 µl of LB medium was added and the cells were incubated at 37°C for 30 
minutes. Cells were then plated out on antibiotic containing media and incubated overnight at 37°C.  
 
 OVERNIGHT CULTURE 3.3.4
Bacteria, picked directly from petri dishes or taken from frozen cultures, were incubated in 4 
ml LB media for mini-preps or in 100 ml LB media for midi-preps with antibiotics and incubated 
overnight at 37°C under aerobe conditions.  
Solutions: 
LB Medium  Ampicillin sodium salt 
(Sigma) 
10 g/l Tryptone 
5 g/l Yeast extract 
10g/l NaCl 
Adjusted to pH 7.0 
 Dissolved in H2O 
100 mg/ml 
 
 ISOLATION OF PLASMID DNA FROM BACTERIA 3.3.5
3.3.5.1  DNA miniprep  
Small-scale isolation of plasmid DNA from bacteria is performed for screening and analysis of 
plasmid DNA in cloning experiments.  A single colony was taken from the transformation plate and 
used to inoculate 4 ml of LB medium containing ampicillin (Sigma, 100 mg/ml) and incubated 
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overnight at 37°C. Bacteria from the overnight culture were harvested by centrifugation at 5000 g for 
5 minutes at 4°C. The pellet of bacterial cells was carefully resuspended in 100 µl re-suspension 
buffer S1 (Solutions from Nucleobond Midipreparation kit). Cell lysis was performed by adding 200 µl 
lysis solution S2 to the cells, inverting the tube and incubating it for two minutes. 150 µl pre-cooled 
neutralization buffer S3 was added to the suspension, again inverting the tube and incubating it for 5 
minutes. Separation of the DNA from cell debris was performed by centrifugation at 13200 rpm for 
10 minutes at 4°C. Supernatant, containing the plasmid DNA was transferred to a new tube and DNA 
was precipitated by addition of 1 ml ice-cold 70% ethanol. After centrifugation at 13200 rpm for 5 
minutes at 4°C, the pellet was resuspended in 200 µl 1x TE buffer and 200 µl 5 M LiCl to precipitate 
remaining RNA and centrifuged at 13200 rpm for 5 minutes at 4°C. Again the supernatant was 
transferred to a new tube and DNA was precipitated as described above. After centrifugation, the 
pellet was dried for 10-15 minutes and DNA was resuspended in 50 µl dH2O. This plasmid quality is 
suitable for analytical digestions.  
Solutions: 
Re-suspension buffer SI  Lysis buffer SII  
Neutralization buffer 
SIII 
 1x TE buffer 
50 mM Tris/HCl, pH 8.0 
10 mM EDTA 
100 µg/ml RNase A 
 20 mM NaOH 
1% (w/v) SDS 
 2.8 M potassium- 
acetate pH5.1 
 10 mM Tris pH 8.0 
 (adjusted with NaOH) 
1 mM EDTA 
 
3.3.5.2 DNA midiprep  
For preparative digestions and sequencing higher amounts of pure plasmid DNA were needed 
and were obtained with the Nucleobond AX plasmid Midi Kit (Macherey-Nagel) used according to the 
instructions of the manufacturer.  
Additional solutions to miniprep: 
Equilibration buffer N2  Wash buffer N3  Elution buffer N5 
100 mM Tris 
15% ethanol 
900 mM KCl 
0.15% Triton X-100 
Adjusted to pH 6.3 with 
H3PO4 
 100 mM Tris 
15% ethanol 
1.15 M KCl 
adjusted to pH 6.3 with 
H3PO4 
 100 mM Tris 
15% ethanol 
1.15 M KCl 
adjusted to pH 8.5 with 
H3PO4 
     
  AGAROSE GEL ELECTROPHORESIS 3.3.6
For the separation and analysis of DNA agarose gel electrophoresis was used. The purpose of 
the gel might be to look at the DNA, to quantify it (see chapter 3.3.6.1) or to isolate a particular band 
(see chapter 3.3.6.2 ).  
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Solutions: 
0.5 x TAE buffer  10 x Loading buffer  Marker  Ethidium bromide 
20 mM Tris base 
5 mM Sodiumacetate 
1 mM EDTA 
 1 mM EDTA 
0.1% Orange G 
10% Ficoll in 0.5 x TAE 
 1 µg of HindIII digested 
λ-DNA (Promega) 
  
 10
-4
% Ethidium 
 bromide in 0.5 x TAE 
 
 DNA separation on agarose gels 3.3.6.1
Agarose was melted in 1x TAE buffer by boiling. Under normal conditions a 1% agarose gel was 
made. After cooling the gel for some minutes it was poured into a gel rack with a comb. When the gel 
was fully polymerized it was put into a tank containing 0.5x TAE buffer.  
Samples, which were loaded on the gel consisted of 2 µl DNA, 2 µl loading buffer and 16 µl 
H2O. The lid and power leads are placed on the apparatus, and current is applied. As DNA molecules 
are negatively charged, they migrate from the negative to the positive pole. Smaller fragments move 
faster than larger ones, thus the DNA fragments are separated according to their size. DNA fragment 
separation normally was performed at 110 V using the Biorad power pack basic. The distance the 
DNA has migrated can be visualized by staining with ethidium bromide, which intercalates between 
bases of DNA and RNA, on an ultraviolet transilluminator.  
 
3.3.6.2 Extraction of DNA from agarose gels 
Desired fragments were cut out from the gel under UV light and isolated and purified from the 
gel using the “Wizard® Gel and PCR Clean up system” by Promega (see 3.3.8.1). 
 
 ENZYMATIC REACTIONS  3.3.7
3.3.7.1 Restriction digestions of DNA 
Digestion of DNA was performed using restriction endonucleases and 10x reaction buffers 
purchased from New England BioLabs according to the manufacturers protocols. Depending on the 
enzymes used, the temperature and the time of incubation was chosen. For efficient analytical 
digestions 5 – 10 µg of DNA were used in a total volume of 100 µl normally composed of:  
     x µl DNA 
   10  µl NE buffer (1-4) 
     1 µl enzyme 
     y  µl dH2O 
 100 µl  
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Preparative digestions were performed with 1-2 µg of DNA in a total volume of 20 µl: 
     x µl DNA 
     2  µl NE buffer (1-4) 
     0.5 µl enzyme 
     y  µl dH2O 
   20 µl   
 
3.3.7.2 Removal of 5’ phosphate groups from DNA with calf intestinal phosphatase 
In order to prevent re-ligation of the vector and thereby increase ligation efficiency, the cut 
vector was subjected to dephosphorylation of the 5’ phosphates of the vector by CIP (calf intestinal 
alkaline phosphatase, New England Biolabs). The restricted and purified vector was eluted in 53 µl 
dH2O and incubated with 1 µl CIP (10 u/µl) and 6 µl NEB 3 (New England Biolabs) at 37°C for 60 
minutes. Afterwards, the reaction mixture was purified using the Clean-Up System (see chapter 
3.3.8.1).  
 
3.3.7.3 Phosphorylation and annealing of oligonucleotides 
Phosphorylation of 5’ ends was carried out using the T4 polynucleotide kinase (PNK, New 
England BioLabs, 10 u/µl). Phosphorylation reactions were performed in a total volume of 20 µl 
composed of:  
  1  µl  Tim XXX (1 µg/µl) 
   1  µl  Tim XXX (1 µg/µl) 
   2  µl  100 mM ATP 
   2  µl  10 x Polynucleotidekinase (PNK) buffer (New England BioLabs) 
   1  µl  T4 PNK (New England BioLabs, 10 u/µl) 
13  µl  dH2O 
20  µl 
 
A single cycle of incubation was performed on a Perkin Elmer DNA Thermal Cycler 480 with the 
following conditions:  
Temperature [°C] Time [min] Step 
37 °C 30 minutes Phosphorylation 
90°C 30 seconds Inactivation 
37°C 5 minutes  
Table 9 Conditions for kinasing of 5’ ends of primers. 
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3.3.7.4 Ligation of DNA fragments with T4 DNA ligase 
To estimate the DNA concentration prior to ligation dephosphorylated vector and insert were 
loaded on an agarose gel. Ideal ratio of vector to insert concentration was about 1:3. Ligation 
reaction were either performed at RT for 2 hours or at 16°C overnight in a total volume of 20 µl 
composed of:  
      50  ng vector 
150 ng / 1 µl  insert / phosphorylation mix  
        2 µl 10 x ligase buffer (New England BioLabs)  
        0.5 µl  T4 DNA ligase (New England BioLabs, 400 u/µl) 
        x     µl  dH2O 
       20 µl  
  
  DNA PURIFICATION  3.3.8
3.3.8.1 Wizard SV Gel and PCR Clean-Up System (Promega)  
Extraction of DNA from agarose gels, as well as the purification of PCR or other DNA samples 
(e.g. after dephosphorylation, restriction) were performed with the Wizard® SV Gel and PCR Clean-
Up System kit from Promega.  
For the extraction of DNA from a gel, the band was isolated from the gel by cutting, followed 
by adding membrane binding solution at a ratio of 10 µl of solution per 10 mg of agarose gel slice. 
The mixture was then incubated at 65°C for 10 minutes or until the gel slice was completely 
dissolved. For purifying PCR or other reaction samples, an equal volume of membrane binding 
solution was added. One SV minicolumn was placed in a collection tube for each dissolved gel slice or 
DNA sample. The dissolved gel mixture or prepared DNA sample was transferred to it and incubated 
for 1 minute at RT. After centrifugation at 13200 rpm for 1 minute, the column was washed by 
adding 700 µl of membrane wash solution. The centrifugation and washing step was repeated by 
adding 500 µl of membrane wash solution. After another centrifugation, the collection tube was 
completely emptied, and the minicolumn was centrifuged at 13200 rpm for 5 minutes. After that the 
minicolumn was transferred to a clean 1.5 ml microcentrifuge tube and 15 µl – 50 ml dH2O was 
added onto the column, incubated for two minutes and centrifuged at 13200 rpm for three minutes. 
The elution, containing the DNA, could then be stored at – 20°C or used for further experiments.  
 
3.3.8.2 Phenol-chloroform extraction 
To remove proteins and other contaminants from DNA 2 µl 0.5 M EDTA pH 8.0 and 100 µl 
phenol were added (per 100 µl of DNA sample). After that the mixture was vortexed and centrifuged 
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at 13200 rpm for two minutes. The aqueous phase was transferred to a new eppendorf tube and 100 
µl of chloroform was added to the tube. Vortexing, centrifuging and transfer to a new eppendorf 
tube was repeated as described above. The purified sample was stored for later use at -20°C (DNA) or 
-80°C (RNA).  
 
  PRECIPITATION OF DNA 3.3.9
DNA was precipitated with 1/10 volume of 3M NaOAc to neutralize the charge on the sugar 
phosphate backbone, making the molecule less hydrophilic and less soluble and 2.5 volumes of 100% 
ethanol. Sodium acetate is used for routing DNA precipitations, whereas for RNA precipitation 
ammonium acetate is used, which facilitates also the removal of dNTPs. The precipitation mix was 
incubated at -80°C for 30 minutes. The tube was then centrifuged at 13200 rpm for 20 minutes the 
pellet was air-dried and resuspended in 25 µl of dH2O. 
 
  QUANTIFICATION OF DNA/RNA  3.3.10
Concentrations and sample purity (260/280) of DNA and RNA were measured using the 
NanoDrop from Thermo Scientific.  
 
  DNA SEQUENCING 3.3.11
Samples for DNA sequencing were prepared. For sequencing of plasmid DNA, samples with 
concentrations of 100 ng/µl were needed. For sequencing DNA of PCR reactions a concentration of 
40 ng/µl was needed. 4 µl of the appropriate primer (1:30 diluted) was added and the sample was 
sent to LGC Genomics.  
 
3.4 RNA METHODS 
3.4.1 IN VITRO TRANSCRIPTION 
Producing RNA from DNA was performed using an in vitro transcription system with the T7 
promoter. First the plasmid DNA was linearized with a restriction enzyme cleaving just downstream 
of the coding sequence. After purification, DNA was eluted in 36 µl dH2O.  
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Transcription reactions were performed in a total volume of 100 µl composed of:  
    36 µl  DNA 
    20 µl  5x PO4/DTT  
    20 µl  2.5 mM NTPs  
    20 µl  Spermidine/Mg  
      3 µl  RNasin® RNase Inhibitor (Promega, 40 u/µl) 
      1 µl  T7 RNA polymerase  
 100 µl 
 
To in vitro transcribe DNA into RNA the reaction mix was incubated at 37°C for 120-180 
minutes. Template DNA was digested by adding 0.6 µl desoxyribonuclease I (Invitrogen, 251 u/µl) 
and 1 µl RNasin® RNase Inhibitor (Promega, 40 u/µl) and incubating it again at 37°C for 20 minutes. 
The RNA was extracted using phenol/chloroform extraction. RNA was precipitated with 1/3 volume 
of 8M NH4OAc and 2.5 volumes of 100% ethanol. The precipitation mix was incubated at -80°C for 30 
minutes. The tube was then centrifuged at 13200 rpm for 20 minutes, the pellet was air-dried and 
resuspended in 25 µl of dH2O. 
 
3.4.2 RNA AGAROSE GEL ELECTROPHORESIS 
The quality of the RNA was checked on a 1% agarose gel containing 0.1% (w/v) SDS. 10x 
loading buffer was added to the RNA samples. To better denature secondary structures, the samples 
were heated to 70°C for 5 minutes, before putting them on ice for some seconds. After loading, RNA 
fragments separation was performed at 100 V using the Biorad power pack 300. Before staining the 
agarose gel in ethidium bromide solution, it was washed two times in dH2O for 15 minutes. RNA 
bands were visualized using an UV transilluminator.  
 
3.4.3 IN VITRO TRANSLATION  
To monitor self-processing of the 2Apro in vitro translation reactions were performed. Thereby, 
in vitro transcribed mRNA, coding for VP-2Apro, was added to rabbit reticulocyte lysate (RRL) and 35S 
methionine, which was used to build the protein during the reaction and could later be detected. 
Aliquots of the newly synthesized viral proteins were taken at determined times.  
In vitro translation reactions were typically performed in reaction volumes of 10 µl (multiplied 
depending on how many aliquots are needed to be taken at different time points) at 30°C. The 
mastermix of a standard reaction was composed out of: 
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   70 µl RRL (rabbit reticulocyte lysate, Promega) 
     2 µl 1 mM amino acid mix without methionine (Promega) 
     2 µl RNasin (Promega, 40 u/µl) 
     4 µl 10 µM 35S methionine (1000 Ci/mmol, Hartmann Analytics) 
   12 µl dH2O 
   90 µl  
 
9 µl of the mastermix were transferred into a new tube containing 1 µl of dH2O and served as a 
negative control. After pre-incubation of the translation mix for two minutes at 30°C, the translation 
was started by the addition of 10 µl in vitro transcribed RNA (10ng/µl). 10 µl aliquots were removed 
after translation start at the following time points: 0, 10, 20, 30, 60, 120 and 180 minutes. The 
reaction was stopped by transferring the aliquots immediately to 41 µl of ice-cold stop solution.  
The translation products were analyzed by the polyacrylamide gel electrophoresis system 
described by Dasso & Jackson (1989) and fluorography. 
Solutions 
Stop solution  2x Laemmli Sample buffer 
1 µl 20 mM Unlabeled  
methionine/cysteine mix  
25 µl 2x Laemmli sample 
15 µl H20 
 20% glycerol 
10% β-mercapto- 
ethanol 
6% SDS 
0.01% Bromophenol  
blue pH6.8 
 
3.4.4 SDS PAGE (DASSO AND JACKSON, 1989) 
In vitro translated products were analyzed on a 17.5% SDS-PAGE followed by fluorography. A 
protocol of sodiumdodecylsulfate polyacrylamide electrophoresis (SDS PAGE) of Dasso and Jackson 
(Dasso and Jackson, 1989) was used to separate protein fragments of smaller size. Composition of 
both gel parts are listed in table 10.  
 17.5 % Separation gel  Stacking gel 
30% Polyacrylamide 3.500 ml 0.333 ml 
2.5 % Bisacrylamide 0.158 ml 0.104 ml 
4 x LGS  1.500 ml - 
4x UGS - 0.500 ml 
dH2O 0.754 ml 1.060 ml 
10% APS 0.050 ml 0.020 ml 
TEMED 0.005 ml 0.002 ml 
 
 
 
 
Table 10 Components of separation and stacking gel of SDS PAGE gel (Dasso and Jackson, 1989). LGS: lower gel solution; 
UGS: upper gel solution; APS: Ammoniumperoxidisulfate; TEMED: N,N,N',N'-tetramethyl-ethane-1,2-diamine. 
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The separation gel was poured and overlaid with 70% ethanol. After polymerization it was 
rinsed with H2O, and the stacking gel was poured on top of the separation gel. Samples were mixed 
with 2x Laemmli sample buffer and heated to 95°C for 10 minutes. The gel unit was assembled and 
the tank of a mini-PROTEAN® 3 system from BioRad was filled with running buffer. After loading the 
samples, protein separation was achieved at 150 V. 5 µl of the 14C-labelled protein marker from 
Perkin Elmer or of the 14C labeled CFA.626 protein marker from Amersham was used as a size marker. 
Solutions 
4x Lower gel 
solution 
 
4 x Upper gel 
solution 
 
Running buffer 
(Dasso and Jackson) 
 2x Laemmli Sample 
buffer 
1.5 M Tris HCl pH8.8  
0.4% SDS 
 0.5 M Tris HCl pH 6.8 
0.4% SDS  
 50 mM Tris/HCl  
385 mM Glycine 
0.1% (w/v) SDS  
 20% Glycerol 
10% β-mercapto- 
ethanol 
6% SDS 
0.01% Bromophenol  
blue pH6.8 
 
3.4.5 FLUOROGRAPHY  
After separation of the 35S-methionine labeled in vitro translated proteins on a Dasso & 
Jackson polyacrylamide gel, the gel was washed two times in enhancer solution for 15 minutes at 
room temperature. By doing this, the wavelength of radiation is shifted, to increase the sensitivity of 
the signal by an autoradiography film and to lower the background. After drying with vacuum on 
WhatmanTM 3MM paper, the gel was exposed to a KODAK BioMax MR film for 16 – 24 hours at -80°C. 
Films were developed on an AGFA Curix 60.  
Solutions 
Enhancer solution  
1 M sodium salicylate 
45% methanol 
 
 
3.5 TISSUE CULTURE 
 CELL LINES AND VIRUS 3.5.1
Human cervix carcinoma HeLa Ohio, which are particularly suited for growth of human 
rhinoviruses, were obtained from the Flow Company and used throughout all experiments.  HRV1A, 
and -14 were thankfully provided by Irene Gösler.  
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 MEDIA AND SOLUTIONS 3.5.2
Growth medium: Minimum essential medium (MEM, Gibco) was supplemented with 10% (v/v) 
fetal calf serum (FCS, Gibco), 1% (v/v) 200 mM L-Glutamine (Gibco), 1% (v/v) 100x penicillin/ 
streptomycin (Gibco). This medium is used for monolayer culture of HeLa cells.  
For virus infectivity assays, MEM was supplemented with 2% (v/v) FCS, 1% (v/v) 200 mM           
L-Glutamine, 1% (v/v) penicillin/streptomycin and 1% (v/v) 3 M MgCl2.  
The buffer used to wash the cells was 1x phosphate buffered saline (PBS) containing 1.4 mM 
KH2PO4, 2.7 mM KCl, 4-3 mM Na2HPO4 and 137 mM NaCl dissolved in H2O.  
For plaque purification and plaque assays a semi solid medium was made, containing 2% low 
melting agarose (Sigma) and 2x Infection medium.  
RNA transfection is performed with DEAE dextran solution and 2x LiCl2 buffer. The DEAE 
dextran stock solution contains 3mg/ml and the 2x LiCl2 buffer contains 0.28 M LiCl2, 2 mM MgCl2, 20 
mM HEPES pH 7.5 (adjusted with NaOH).  
To dissociate adherent cells from tissue culture dishes a buffered salt solution containing 0.5% 
(w/v) trypsin and 0.2% (w/v) EDTA is used (PAA Laboratories GmbH).  
 
 CULTIVATION OF MAMMALIAN CELLS 3.5.3
Adherent HeLa cells were cultured as monolayers in tissue culture flasks, petri-dishes or micro 
titer well plates (Nunc, Corning) in MEM supplemented with FCS, glutamine and antibiotics (see 
chapter 3.5.2) at 37°C in presence of 5% CO2.  
For splitting confluent cells, the petri-dish or flasks had to be washed once with warm 1x PBS 
to completely remove old media and dead cells and incubated with 3 ml Trypsin/EDTA for 5 minutes 
at 37°C to dissociate from the surface. Floating cells were then resuspended in growth medium to 
stop the activity of trypsin/EDTA and were diluted to the preferred density.  
6-well plate, 2 ml media per well  
96-well plate, 100 µl media per well 
T25 cm2 flask, 50 ml media 
T75 cm2 flask, 50 ml media  
 
 DETERMINATION OF CELL NUMBERS 3.5.4
After the cells were detached from the flask surface, they were centrifuged 5000 rpm for 5 
minutes and the cells were taken up in a known volume of fresh infection medium. 100 µl of the cell 
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suspension was mixed with 400 µl trypan blue and loaded onto a thoma haemocytometer. The cells 
were counted under the light microscope.  
 
 FREEZING AND THAWING CELLS 3.5.5
Cells were pelleted by centrifugation for 5 minutes at 1200 rpm and about 107 cells were 
resuspended in 1 ml heat inactivated FCS containing 10% DMSO and were transferred into cryotubes. 
The tubes were frozen in a cryobox containing isopropanol at -80°C overnight and on the next day 
transferred into liquid nitrogen (-196°C).  
Thawing of the frozen stocks was performed quickly at 37°C, and the cells were resuspended in 
10 volumes of appropriate growth medium and centrifuged for 5 minutes at 1200 rpm. Then they 
were resuspended in fresh growth medium and transferred into a tissue culture flask.  
 
 INFECTING CELLS 3.5.6
One day prior to infection HeLa cells were prepared by seeding a determined amount of cells 
in petri dishes or flasks. Normally cells were seeded in infection medium to obtain a density of 50% 
on the following day.  
Plastic ware Surface area Number of HeLa cells 
T-175 175 cm2 280 ∙ 105 cells 
T-75 75 cm2 120 ∙ 105 cells 
T-25 25 cm2 40 ∙ 105 cells 
6-well plate 9.4 cm2/well 15 ∙ 105 cells/well 
12-well plate 4 cm2/well 6.4 ∙ 105 cells/well 
24-well plate 2 cm2/well 3.2 ∙ 105 cells/well 
48-well plate 0.8 cm2/well 1.3 ∙ 105 cells/well 
96-well plate 0.32 cm2/well 0.51 ∙ 105 cells/well 
 
Table 11 Tissue culture dishes. Cell number corresponding to the surface of culture flasks/plates used (1 cm
2
 ~ 1.6 ∙ 10
5
 
HeLa cells) 
 
On the day of infection cells were washed two times with 1x PBS and virus dilution harvested 
after transfection or infection was added. After incubation for 90 minutes at 34°C and 5% CO2 the 
supernatant was removed and the cells were washed two times with 1x PBS and 2 ml fresh infection 
medium was added and incubated for 48-72 hours.  
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 CELL TRANSFECTION BY DEAE-DEXTRAN 3.5.7
For the introduction of RNA into eukaryotic cells the transient DEAE-dextran mediated 
transfection was used, which facilitates RNA binding to the cell membranes and entry of the RNA into 
the cell via endocytosis.  
HeLa cells were prepared for transfection by seeding 0.325 106 cells per 6-well in 2 ml infection 
medium. Cells were grown for 18-24 hours at 37°C until a density of 50% was reached.  
The transfection mix (for each 6-well) was prepared with the following components: 1.2 µg in 
vitro transcribed RNA diluted in 55 µl, 175 µl 2x LiCl2 and 110 µl 3mg/ml DEAE-dextran. The resulting 
mix was incubated for 30 minutes on ice. For MOCK transfection 55 µl water was used instead of 
RNA. Meanwhile cells were washed two times with 1x PBS and 300 µl of transfection/MOCK 
transfection mix was added to the cells and incubated for 25 minutes at 34°C with light shaking. Then 
the transfection mix was removed, the cells were washed two times with 1x PBS and 3 ml of fresh 
infection medium or 3 ml of an 1:1 mix of 2% agarose and 2x infection medium was added and the 
plate was incubated for 2-3 days at 34°C, 5% CO2.  
 
 CELL TRANSFECTION USING LIPOFECTAMINE 2000 TRANSFECTION REAGENT 3.5.8
Cells were seeded the day prior to infection as described in 3.5.7. On the day of infection 1.2 
µg of RNA was mixed with 250 µl OptiMEM (Invitrogen) per well and 8 µl of Lipofectamine 2000 
(Invitrogen) was also gently mixed with 250 µl OptiMEM per well and incubated at room 
temperature for 5 minutes. Then the RNA/OptiMEM was mixed with the Lipofectamine/OptiMEM 
and left at room temperature for 20 minutes. Meanwhile, cells were rinsed with 1x PBS and 500 µl of 
warm OptiMEM was added to each well, before distributing the RNA/lipofectamine mixture over the 
cells. With gentle agitation the plates were incubated at room temperature for 15 minutes, followed 
by an incubation of 45 minutes at 34°C. Transfection medium was aspirated off, cells were rinsed 
with 1x PBS and 3 ml of fresh infection medium or 3 ml of a 1:1 mix of 2% agarose and 2x infection 
medium was added and the plate was incubated for 2-3 days at 34°C, 5% CO2.  
 
  VIRUS INFECTIVITY ASSAYS 3.5.9
3.5.9.1 Viral titer determination by TCID50 
HeLa cells were seeded in a 96-well plate (1.3 104 cells per well in 100 µl infection medium) 
one day prior to infection to be about 50% dense on the day of infection.  
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On the day of infection serial dilutions of the virus sample of unknown titer was prepared in 2 
ml infection medium. Cells were infected with 100 µl per well of the virus dilutions (12 wells for each 
of the 8 dilutions). After incubation time of 5 days at 34°C, 5% CO2 the supernatant was discarded 
and the remaining cells were stained with 100 µl 0.1% crystal violet in H2O for about 10 minutes. 
Staining solution was discarded and the cells were washed with water. Infected wells remained 
unstained because lysed cells detach from the surface and were washed away, whereas uninfected 
cells were stained violet. By the number of infected wells in each dilution the tissue culture infective 
dose 50 (TCID50) per ml of the virus sample could be calculated (Blake and O'Connell, 1993).  
It has been experimentally determined that 10 TCID50 equal approximately 1 plaque forming 
unit (pfu). 
 
3.5.9.2 Plaque assays 
HeLa Ohio cells were seeded in 6-well plates (0.325 106 cells per well in 2 ml infection medium) 
to be about 50% dense on the day of infection.  
On the day of infection, virus dilutions were prepared in 1 ml infection medium. The medium 
from the 6-well plates was aspirated and the wells were washed twice with PBS. Then, 1 ml of virus 
dilution/MOCK dilution was added and the plates were incubated for 90 minutes at 34°C, 5% CO2. 
The virus dilutions were aspirated, the cells were again washed twice with PBS and 3 ml of semi-solid 
medium (consisting of 1.5 ml of pre-warmed 2x infection medium and 1.5 ml pre-warmed 2% low 
melting type agarose) was added quickly to each well. The plates were further incubated at 34°C, 5% 
CO2 until plaques were visible under the microscope or after three days.  
For the isolation of mutant viruses the following procedure was performed: the wells were 
then stained with 1 ml of a sterile 0.05% neutral red solution in PBS for 1 hour at 34°C. After 
removing the neutral red solution, plaques were visible as unstained spots in the red cell monolayer. 
Those plaques were then picked with a Pasteur pipette and resuspended in 1 ml infection medium. 
Those plaques were then frozen and thawed three times, before starting a new round of plaque 
purification. For isolation of mutant viral plaques, three rounds of plaque purifications were 
performed. After the last round the picked plaques were resuspended in 100 µl PBS instead of 
infection medium before synthesizing cDNA via RT-PCR (see chapter 3.3.1.3).  
The overlay medium could then be removed and the underlying cells were then stained with 
0.1% crystal violet solution to count the plaques.  
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3.5.9.3 Growth kinetics 
HeLa cells were seeded in lose 6-wells (0.325 106 cells per well in infection medium) to be 
about 50% dense on the day of infection.  
On the day of infection medium was aspirated and the cells were washed twice with PBS. 1.5 
ml of a virus dilution with an MOI of 1 (6.5 105 pfu/ml) was added to each well and the cells were 
incubated for 90 minutes at 34°C, 5% CO2. Unbound virus was then removed by aspirating the virus 
suspension and the cells were washed twice with PBS. 1.5 ml fresh infection medium was added and 
the wells were then further incubated at 34°C, 5% CO2. Two samples (intracellular and extracellular 
virus) was frozen immediately (0 hours post infection). After 3h, 6h, 8h, 24h and 48h the other 
samples were taken. To distinguish between intracellular and extracellular virus, the supernatant 
containing the free or extracellular virus was frozen separately. To the cells containing the 
intracellular virus 1.5 ml of fresh infection medium was added before freezing. After three 
freeze/thaw cycles, the virus titer of each sample was determined by TCID50.  
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4 RESULTS 
           
4.1 SEQUENCE COMPARISON OF ENTEROVIRAL 2APRO   
The 2Apro of various different Enteroviruses is a protein composed of 142 to 149 amino acids. 
Sequence comparison of the 2Apro of human rhinovirus A (HRVA-1a, HRVA-2), human rhinovirus B 
(HRVB-14), human rhinovirus C (HRVC-1), poliovirus (PV-1), coxsackievirus B (CVB-4) and enterovirus 
(EV-71) show only an identity at the amino acid level of about 23% (see Figure 15A).  
 
                            
Figure 15 Amino acid sequence alignment of 2A
pro
 of different picornaviruses. A) Conserved residues are represented in 
blue.  The active site residues of HRV2 2A
pro
 are marked with a red arrow: His, Asp, Cys.  The residues coordinating the zinc 
ion are marked with a dark blue arrow.  The sequences were taken from the database www.ncbi.nlm.nih.gov. Sequence IDs: 
AY458604 (HRV-A 1a), X02316.1 (HRV-A 2), X01087 (HRV-B 14), EF582387.1 (HRV-C 26) ABV60422 (PV 1), DQ480420 (CV-B 
4), U22521.1 (EV 71). The sequence alignment was made online using ClustalW (http://www.ebi.ac.uk/Tools/msa/ 
clustalw2/) and edited with the programme BioEdit. PV poliovirus, CV coxsackievirus, HRV human rhinovirus, EV 
enterovirus. B) Ribbon diagram and C) surface representations of the 2A
pro
 showing conserved residues from selected 
picornaviruses identified from the sequence alignment in Figure 15A. Identical residues are colored on the HRV2 2A
pro
 in 
blue. Non homologous residues are shown in grey. Conserved residues are mainly on the C-terminal part of the protein. 
Only single residues in the N-terminal part are conserved. Created with Pymol (DeLano, 2002) using the PDB ID code 2HRV2. 
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The catalytic triad of the active site residues was determined for HRV2 2Apro to consist of 
His18, Asp35 and Cys106 (Sommergruber et al., 1997; Petersen et al., 1999), for PV 2Apro the residues 
are His20, Asp38 and Cys109 (Yu and Lloyd, 1991). These three residues are conserved in all 
Enteroviruses. On the opposite face of the active site at the beginning of the C-terminal region is the 
zinc binding site (Peterson 1999), in which a zinc ion is coordinated by three Cys sulfurs (Cys52, Cys54 
Cys112) and one His nitrogen (His114) to stabilize the 2Apro to form an active enzyme (Voss et al., 
1995). These residues are conserved in all shown picornaviral 2Apro sequences (Figure 15A, dark blue 
arrow). Other conserved residues are mainly located on the C-terminal part of the protein and only 
certain specific residues are identical in the N-terminal part. In Figure 15B and C, HRV2 2Apro is used 
as a model to show the localization of conserved residues from the sequence alignment.  
The self-processing reaction of the 2Apro is the first cleavage event during protein synthesis 
(Toyoda et al., 1986) and leads to a separation of the structural proteins from the non-structural 
ones. The cleavage site, consisting of at least five residues of the C-terminal part of VP1 (also 
designated as the P site according to Schechter and Berger, 1967) and at least four residues of the N-
terminal part of the 2Apro (also designated as the P’ site), is recognized by the 2Apro and cleaved. 
Figure 12 (in chapter 1.6.3) gives an overview of some enteroviral serotypes and their respective 
cleavage sites on the polyprotein. By comparing the cleavage site of different picornaviruses, no 
appreciable identity between the residues can be seen. The only absolutely conserved residue is the 
Gly at position P1’. At position P4, sequences shown here contain a Leu or an Ile and an amino acid 
with a hydrophobic side chain at position P1. All other positions show many diverse residues such as 
hydrophobic amino acids and amino acids with polar or charged side chains. It was shown for HRV2 
2Apro that, upon substrate entry into the binding cleft Thr at the P2 position makes a hydrogen bond 
to Ser83 from the dityrosine flap, which is thought to compensate for the rotation of Tyr85 away 
from its original position, stacked upon His18 (Petersen et al., 1999).  
Figure 16A shows a comparison of the 2Apro sequence of a HRV group A, group B and group C 
virus. Although the overall sequence of HRV-C group is substantially different from other classified 
species, the 2Apro sequence of HRV-C and HRV-A share some homologies. In fact, Simmonds et al. 
(2010) showed that the C-terminal domain of HRV-A and HRV-C have undergone interspecies 
recombination, whereas the N-terminal part is species-specific (McIntyre et al., 2010; Simmonds et 
al., 2010).  Figure 16B, C and D show the cleavage site of all HRV group A, B or group C viruses. In 
HRV-A group viruses, the C-terminal VP1 part of the cleavage site seems rather amenable to 
accepting various residues at those positions, whereas the N-terminal 2Apro part is nearly completely 
conserved. The first residues P1’ and P2’ are the hydrophobic amino acids Gly and Pro, which are 
conserved in all HRV-A group viruses. In contrast, HRV-B group viruses have three completely 
conserved residues, two in the C-terminal VP1 part of the cleavage site: Ile at position P4 and Tyr at 
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position P1. Additionally, the Gly at position P1’ in the N-terminal 2Apro part of the cleavage site is 
also invariable. HRV-C group viruses show a rather similar cleavage site to that of HRV-A group 
viruses. Gly at position P1’ seems to be completely required as it is conserved in all serotypes. 
  
 
  
Figure 16 Comparison of the 2A
pro
 sequence and cleavage sites of 2A
pro
 of HRV group A, B and C viruses . A) Sequence 
alignment of the 2A
pro
 of HRV1A (group A), HRV14 (group B) and HRV26 (group C).  The sequences were taken from the 
database www.ncbi.nlm.nih.gov. Sequence IDs: AY458604 (HRV-A 1a), X01087 (HRV-B 14), EF582387.1 (HRV-C 26). The 
sequence alignment was made online using ClustalW (http://www.ebi.ac.uk/Tools/ msa/clustalw2/) and edited with the 
programme BioEdit. HRV human rhinovirus. B) Comparison of cleavage site of all human rhinovirus group A viruses. C) 
Comparison of cleavage site of all human rhinovirus group B viruses. D) Comparison of the 2A
pro
 cleavage site of all human 
rhinovirus group C viruses. The P site representing the C-terminus of VP1 is shown as 1-5 here. The P’ site representing the 
N-terminus of 2A
pro
 is shown as 6-9 here. The sequence logo was generated by using WebLogo (Crooks et al., 2004). HRV 
human rhinovirus. 
 
For the development of an antiviral inhibitor against this protein, it is nevertheless necessary 
to fully understand how the 2Apro recognizes the cleavage site, which residues are involved in this 
recognition and which are involved in the cleavage reaction. Experiments in this thesis were aimed 
towards this goal. 
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4.2 PROTEOLYTIC ACTIVITY OF WILD TYPE HRV1A 2APRO  
The cis-cleavage event of wild type HRV1A 2Apro from its precursor VP1-2Apro occurs as soon as 
the 2Apro is generated during protein synthesis. In the course of this work, the cleavage was 
monitored by translating a suitable RNA encoding VP1 and 2Apro in RRLs. The 48 kDa precursor VP1-
2Apro, the initial translation product, is cleaved to yield equimolar amounts of 32 kDa VP1 and 16 kDa 
2Apro cleavage products.  
Figure 17 shows the kinetics of protein translation and self-cleavage of the HRV1A wt 2Apro in a 
typical experiment. Translation of mRNA into protein is already apparent after 10 minutes, having 
started between 0 and 10 minutes. After 10 minutes, 50% of the VP1-2Apro precursor is already 
cleaved; cleavage is nearly complete after 120 minutes. The band of the 2Apro is only weakly detected 
by fluorography, as it only contains 1 Met residue labeled during protein translation with 35S 
methionine, whereas VP1 contains eight. 
 
 
 
 
 
Figure 17 Proteolytic activity of 2A
pro
 wild type. A) Translation into protein was monitored at 30°C by using rabbit 
reticulocyte lysate which were programmed with RNA (10 ng/µl) coding for VP1-2A
pro
. As a negative control, water instead 
of RNA was used. At the indicated time points, 10 µl aliquots were taken and translation reaction were stopped by adding 
an ice-cold stop solution containing 25 µl 2x Laemmli sample buffer, 15 µl H2O and 1 µl unlabeled methionine/cysteine (20 
mM). Viral proteins were separated on a 17.5% Dasso & Jackson PAA gel and visualized by fluorography after an exposure 
time of 16 hours. The 
14
C-methylated protein marker (M) from Perkin Elmer was used and size is shown in kDa. Uncleaved 
VP1-2A
pro
 and the cleavage products VP1 and 2A
pro
 are marked by arrows. B) Schematic of the cleavage of the initial 
translation product into VP1 (red) and 2A
pro
 (blue). The cleavage site is indicated. 
 
4.3 CONSTRUCTION OF HRV1A 2APRO  MUTANTS 
In the first experiment, the cleavage site of HRV1A VP1-2Apro, T I T T A * G P S D was replaced 
by the corresponding region of HRV14 VP1-2Apro, D I K S Y * G L G P. HRV1A and HRV14 are serotypes 
of human rhinoviruses, belonging to genetic groups A and B respectively. As the 2Apro of HRV1A and 
HRV14 show only 42% identity in their amino acid sequence, we wanted to find out whether the 
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HRV1A enzyme could cleave at the rather different HRV14 cleavage site. Thus, in Figure 18, the 
cleavage site of HRV1A, T I T T A * G P S D, was replaced by the corresponding region of HRV14, D I K 
S Y * G L G P. 
 
Figure 18 Self-processing of HRV1A 2A
pro
 on cleavage sites containing residues that differ from the wild type cleavage 
site. In a first attempt the cleavage site was exchanged with the entire cleavage site found in HRV14. Amino acids which 
differ from the wt HRV1A 2A
pro
 cleavage site are underlined. The procedure is the same as described in Figure 17.   
 
Translation was monitored by autoradiography to investigate whether the 2Apro of HRV1A was 
still able to recognize the cleavage site of HRV14. Figure 18 shows that no cleavage products were 
observed within 300 minutes of in vitro translation when the whole sequence of the HRV14 cleavage 
site was exchanged in the HRV1A VP1-2Apro. Therefore, it can be concluded that HRV1A cannot 
accept the HRV14 cleavage site (D I K S Y * G L G P) in cis.  
We next wanted to find out which residues of the HRV14 cleavage site could not be recognized 
by the HRV1A 2Apro. To this end, other constructs with different combinations of amino acids were 
produced and tested for their ability to perform this cleavage event. Table 12 gives an overview of 
the mutated cleavage sites used in the HRV1A VP1-2Apro junction.  
 
             
 
 
 
 
 
Serotype VP1 
P5 P4 P3 P2 P1 
 2Apro 
P1’ P2’ P3’ P4’ 
HRV 1a wt  T     I    T    T    A *  G    P     S     D 
HRV 14 wt   D    I    K    S    Y *  G    L     G     P 
HRV 1A mutant 1  D    I    K    S    Y *  G    P     S     D 
HRV 1A mutant 2  T     I    T    T    A *  G    L     G     P 
HRV 1A mutant 3  T     I    K    S    Y *  G    L     S     D 
HRV 1A mutant 4  T     I    T    S    Y *  G    L     S     D 
HRV 1A mutant 5  T     I    T    T    A *  A    P     S     D 
Table 12 Overview of the HRV1A VP1-2A
pro
 constructs with wt and mutated cleavage site of the 2A
pro
. C-terminus of VP1 
and N-terminus of 2A
pro
 are shown. Underlined residues in the HRV1A mutants differ from wild-type sequence and are, 
except for the last one, all found at equivalent positions at the HRV14 2A
pro 
cleavage site.  
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The HRV1A VP1-2Apro constructs contained combinations of some HRV14 2Apro residues 
upstream and downstream of the cleavage junction. In one construct, Gly, which was exclusively 
found in nearly all picornaviruses at position P1’, was replaced by Ala. Alanine, a very abundant 
amino acid, is only slightly larger than Gly as it possesses a methyl group as side chain in place of  a 
single hydrogen atom.   
To monitor in vitro cleavage of the 2Apro from the VP1-2Apro precursor containing substituted 
cleavage sites, these were exchanged by cassette cloning and mutations were confirmed by 
nucleotide sequence analysis. Following this, the linearized template was transcribed into mRNA and 
in vitro translated into protein.  
 
4.4 CLEAVAGE OF HRV1A VP1-2APRO  CONTAINING SUBSTITUTIONS 
AT THE CLEAVAGE SITE OF THE 2APRO  
We compared the HRV1A VP1-2Apro wt cleavage with the cleavage of VP1-2Apro constructs 
where parts of the HRV14 cleavage sites were exchanged: Figure 19A shows the cleavage when T I T 
T A * G P S D was replaced by only the VP1 part of HRV14, D I K S Y * G P S D (mutant 1). And Figure 
19B shows the cleavage, when T I T T A * G P S D was replaced by only the 2Apro part of HRV14, T I T T 
A * G L S D (mutant 2).  
 
Figure 19 Self-processing of HRV1A 2A
pro
 on cleavage sites containing residues that differ from the wild type cleavage 
site. Here the cleavage sites were exchanged with parts of the cleavage site of the HRV14 2A
pro
. A) P5-P1 of the cleavage 
site mutated to that found in HRV14. B) P1’-P4’ of the cleavage site mutated to that found in HRV14. Amino acids which 
differ from the wt HRV1A 2A
pro
 cleavage site are underlined. The procedure is the same as described in Figure 17.  
 
Different results to that when the full HRV14 wt cleavage site was exchanged, are obtained 
when only one (either the VP1 or the 2Apro) part was exchanged (Figure 19A and B), where only 
kinetics of cleavage is slightly delayed. Introduction of the VP1 part of HRV14 (D I K S Y instead of 
HRV1A T I T T A) into the HRV1A VP1-2Apro cleavage site shows a 50% conversion into the cleavage 
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product after 20 to 30 minutes, which is slightly slower than with HRV1A wt (compare Figure 17). 
Complete cleavage was not finished within 300 minutes of translation. Introduction of the 2A part of 
HRV14 (G L G P instead of HRV1A G P S D) into the HRV1A VP1-2Apro cleavage site shows nearly the 
same cleavage kinetics with 50 % conversion into the cleavage products being reached after about 30 
to 40 minutes. Complete cleavage was also not finished within 300 minutes of translation. 
These cleavage results reveal that HRV1A 2Apro is not able to accept the HRV14 cleavage site. 
Furthermore, the results suggest that mutations upstream and downstream of the cleavage bond will 
be necessary to completely stop the cis-cleavage event of the 2Apro. Mutation of either site alone 
does not impair the activity of the 2Apro.  
As the previous experiments have suggest that mutations upstream and downstream of the 
cleavage bond are necessary to impair the self-processing of the 2Apro, combinations of single amino 
acid changes were therefore used to investigate this influence. In Figure 20A, the P3-P1 (T T A) and 
the P2’ (P) amino acids were replaced by the corresponding amino acids of HRV14 cleavage site (K S 
Y, and L respectively, mutant 3). It shows that cleavage was drastically blocked when amino acids at 
P3-P1 (T T A) and P2’ (P) were replaced by the corresponding residues of HRV14 wt (K S Y and L, 
respectively), indicating that HRV1A 2Apro is no longer able to process this cleavage site. 
Figure 20B shows the cleavage when only P2-P1 (T A) and the P2’ (P) amino acids were 
replaced by the corresponding amino acids of HRV14 cleavage site (S Y and L respectively, mutant 4).  
Again, cleavage was shown to be blocked with this mutated cleavage site. Although, after 20 minutes 
of in vitro translation, some cleavage products of VP1 could be detected, most amount of precursor 
VP1-2Apro was not cleaved within the 300 minutes of in vitro translation.  
This indicates that mutations on both sides are necessary to inhibit the self-processing 
reaction. Mutations at P2-P1 and additionally mutating Pro at P2’ to Leu severely effects cleavage.   
 
Figure 20 Self-processing of HRV1A 2A
pro
 containing several substitutions at the cleavage site. Parts of the cleavage site of 
HRV14 2A
pro
 were used. A) P3-P1 amino acids of the cleavage site were exchanged from Thr to Lys, from Thr to Ser and from 
Ala to Tyr respectively and P2’ amino acid was exchanged from Pro to Leu. B) P2-P1 amino acids of the cleavage site were 
exchanged from Thr to Sere and from Ala to Tyr respectively and P2’ amino acid was exchanged from Pro to Leu. Amino 
acids which differ from the wt HRV1A 2A
pro
 are underlined. The procedure is the same as described in Figure 17. 
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Gly, as the only totally conserved residue in the cleavage site of picornaviruses seems to be 
indispensable for the self-processing reaction of the 2Apro. Several amino acid changes at this P1’ 
(Glu, Lys, Thr, Trp, Phe, Asp) completely blocked the self-cleavage process (Skern et al., 1991; 
Sommergruber et al., 1992) suggesting the strong requirement of Gly at this site. Nevertheless, it was 
tested whether the single addition of a methyl group was able to totally disrupt self-processing by 
replacing the Gly at position P1’ with Ala (mutant 5). The presence of Ala led to a total disruption of 
self-processing activity (Figure 21).  
 
Figure 21 Self-processing of HRV1A 2A
pro
 containing only one substitution at the cleavage site. P1’ amino acid was 
changed from Gly to Ala. The procedure is the same as described in Figure 17.   
 
In Table 13, results of the self-processing reactions of HRV1A 2Apro cleavage site mutants are 
summarized.  
 
 
 
 
 
 
4.5 ISOLATION AND CHARACTERIZATION OF HRV1A SECOND SITE 
REVERTANTS  
For transfection into HeLa cells, three different cleavage site mutants were chosen and cloned 
into the full length clone of HRV1A via cassette cloning: 
Serotype VP1 
P5 P4 P3 P2 P1 
 2Apro 
P1’ P2’ P3’ P4’ 
Cleavage 
efficiency 
HRV 1a wt  T     I    T    T    A *  G    P     S     D ++ 
HRV 14 wt   D    I    K    S    Y *  G    L     G     P - 
HRV 1A mutant 1  D    I    K    S    Y *  G    P     S     D + 
HRV 1A mutant 2  T     I    T    T    A *  G    L     G     P + 
HRV 1A mutant 3  T     I    K    S    Y *  G    L     S     D - 
HRV 1A mutant 4  T     I    T    S    Y *  G    L     S     D - 
HRV 1A mutant 5  T     I    T    T    A *  A    P     S     D - 
Table 13 Overview of the cleavage efficiency of the HRV1A VP1-2A
pro
 constructs. In vitro translation experiments are 
summarized and the results of their cleavage efficiency are shown. (++) indicates wild type cleavage; (+) indicates good 
cleavage and (-) indicates no cleavage during in vitro translation.  
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1) Full HRV14 cleavage site exchanged (D I K S Y * G L G P); this cleavage site was chosen 
because cleavage was completely blocked by these multiple changes in the cleavage site. 
Therefore, we were interested to see whether virus is able to cope with many mutations in 
the cleavage site, and might be able to evolve in order to recover 2Apro function.  
2) Combinations of mutations upstream and downstream of the cleavage bond by HRV14 
amino acids (T I T S Y * G L S D); this hybrid HRV2/HRV14 cleavage site was chosen because 
it was the lowest combination of changes on both sides of the cleavage site that were 
shown to inhibit HRV1A 2Apro self-processing (Table 13). As we were interested in isolating 
escape mutants, we thought that the fewer mutations necessary to change for the virus to 
regain functionality of the 2Apro, the more multiple second site revertants would be 
obtained.  
3) The single addition of methyl group at the P1’ position (T I T T A * A P S D); this single 
mutation was chosen as Gly, as the only completely conserved residue in Enteroviruses, 
had previously been shown in vitro to be irreplaceable. We therefore wanted to 
investigate whether virus is able to introduce a second site mutation in order to keep the 
Ala at this position or whether it would change Ala back to the wt Gly.  
During these studies we wanted to isolate second site revertants that should help us to 
identify structural changes in the mutant and non-functional 2Apro that have recovered their 
biological activity. There are two possible pathways the virus can proceed in order to regain 
functionality. Both pathways rely on the high mutation rate of RNA viruses. One is when the specific 
defect in the primary mutant is changed back to the original amino acid; the other is when a 
mutation elsewhere in the protein is introduced (called a second site revertant). Second site 
revertants might reveal structurally important residues that could be positioned in the cleavage site 
or active site of the 2Apro. 
 
4.7.1 GROWTH PHENOTYPE OF HRV1A CLEAVAGE SITE MUTANTS  
HeLa cells were transfected with HRV1A wt RNA as well as those from the three cleavage site 
mutants. After incubation at 34°C for 2-3 days, plaques were visible under the agar on HeLa 
monolayers in some of the wells (see Figure 22). The transfection well with HRV1A wt was already 
stained after two days; therefore wt plaque sizes are not comparable with those of HRV1A cleavage 
site mutants, which were stained after three days.  
When the HRV1a VP1-2Apro junction was replaced by corresponding amino acids from HRV14 
(D I K S Y * G L G P), no plaques were obtained. Thus, these mutations do not only severely impair 
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self-processing in vitro; probably, there would also be too many changes necessary to restore 
cleavage activity.  
However, plaques were detected after the transfection with HRV1A genome containing 
combinations of the HRV14 cleavage site (T I T S Y * G L S D) as well as after the transfection with 
HRV1A genome containing only the single addition of a methyl group in the P1’ position (T I T T A * A 
P S D).  
 
Figure 22 Effect of mutations on HRV1A growth and spread. Plaque phenotypes on HeLa cells of HRV1A wt and mutant 
viruses with exchanged cleavage sites of the 2A
pro
 are shown. HeLa cells were seeded one day prior to transfection. 1200 ng 
RNA for wt and 8000 ng RNA for mutants was transfected at 34°C for 25 minutes and incubated at 34°C for 2-3 days under 
agar overlay: an uninfected well, cells transfected with HRV1A wt (only two days of incubation), HRV1A with a cleavage site 
of the 2A
pro
 consisting of DIKSY*GLGP, HRV1A with a cleavage site of the 2A
pro
 consisting of TITSY*GLSD and HRV1A with a 
cleavage site of the 2A
pro
 consisting of TITTA*APSD are shown. Residues different to wt residues are underlined.  
 
4.7.2 ISOLATION OF VIRAL PLAQUES 
Plaques were then isolated from the HRV1A viruses with the cleavage sites T I T S Y * G L G P 
and T I T T A * A P S D. This was done by overlaying the cells with a semi-solid medium after 
transfection, which prevents the virus from spreading indiscriminately. A viral plaque is formed when 
one cell is infected within the fixed cell monolayer, lyses after infection and spreads the infection 
only to adjacent cells where the infection to lysis cycle is repeated. Plaques are therefore an area of 
infected cells surrounded by uninfected cells, and are considered to display only one population of 
virus. This is important for the later identification of the sequence of the cDNA of isolated virus.   
Plaques isolated after the transfection were supposed to still carry the mutated cleavage site 
but should have also introduced a second site mutation somewhere in the cleavage site or the 2Apro 
to restore cleavage activity and therefore be able to infect surrounding cells.  To investigate this, 
after three rounds of plaque purification, viral RNA was reverse transcribed into cDNA by RT and the 
cDNA amplified by PCR. The PCR product synthesized completely covers the 2Apro and short regions 
of the neighboring VP1 and 2B protein.  
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4.7.3 LOCALIZATION OF MUTATIONS IN THE SECOND SITE REVERTANTS  
Sequences of plaques of the HRV1A cleavage site mutant carrying combinations of the HRV14 
cleavage site (T I T S Y * G L S D) revealed three different outcomes (Table 14). 
 
Table 14 Sequence of second site revertants isolated by plaque purification; after three rounds plaques isolated were 
reverse transcribed and amplified by RT-PCR and sent for sequencing. Amino acids changed from the original sequence are 
shown in red. 
 
Six out of ten sequences identified contained a Cys in the P1 position. As Tyr is a rather bulky 
amino acid compared to the original Ala residue in the HRV1A P1 position, which may hinder self-
processing due to steric hindrance, it was not greatly surprising that this amino acid was changed to a 
smaller one. By looking in detail at the simplest single base transition possible in this region, Cys was 
identified as being the most likely amino acid change in this P1 position (Table 15). Mutation of only 
one purine base change (AG) is required to change Tyr into Cys.  
 
Table 15 Base transitions possible in the P1 position of HRV1A cleavage site mutant containing combinations of amino 
acid residues from HRV14 2A
pro
 cleavage site (T I T S Y * G L S D). Tyr in the P1 position was exchanged for Cys, which was 
identified to be the smallest amino acid possible where only a single base transition was performed. However, double base 
transitions would also yield Cys as the smallest amino acid possible in this position.  
 
Three further sequences contained a Pro at position P2’ instead of Leu, which was the original 
amino acid in the HRV1A wt cleavage site. As shown previously (see Figure 18, 19A and B), modified 
residues upstream and downstream of the cleavage bond are necessary to completely stop activity of 
the 2Apro. A single base transition in this P2’ position yields Pro as the simplest amino acid possible 
(Table 16).  To replace Leu by Ser in this P2’ position, two base transitions would be necessary.  
 
66 
 
Table 16 Base transition possible in the P2’ position of HRV1A cleavage site mutant containing combinations of amino 
acid residues from the HRV14 (T I T S Y * G L S D). Leu in the P2’ position was changed back to the original amino acid 
Pro, which was identified as being the smallest amino acid possible in which only a single base transition was performed.  
 
One sequence was identified that carried the original exchanged cleavage site (T I T S Y * G L S 
D), but had no additional second site mutation elsewhere in the 2Apro or 2B. When comparing in vitro 
cleavage data (Figure 20B), it can be seen that cleavage of the precursor VP1-2Apro is carried out to a 
very small extent by the HRV1A 2Apro. This suggests that, although it is not very likely that self-
processing by the 2Apro happens with this mutated cleavage site, it is in a few cases sufficient. 
However, compensatory mutations outside the VP1/2A/2B region cannot of course be ruled out.   
Sequences of plaques of the HRV1A cleavage site mutant carrying an Ala in the P1’ position 
instead of Gly revealed that all viruses isolated had changed the Ala mutation back to the original 
amino acid Gly. Changing Ala back to Gly in the P1’ position needs one transition and one 
transversion reaction (Table 17).  
 
Table 17 Reactions necessary to change Ala back to the original amino acid Gly: Transition (A  G) and transversion     
(C  T) reaction. 
 
 
4.6 INFLUENCE OF VP1 Y289R MUTATION AND 2B I94N MUTATION 
ON HRV14 2APRO  CLEAVAGE  
In another approach, experiments for HRV14, a human rhinovirus of the group B, were 
performed to obtain second site revertants that could reactivate non-functional 2Apro. The rationale 
was that HRV14 transfection efficiency in HeLa cells is higher than with HRV1A possibly leading to an 
increase in the efficiency of revertant isolation.  
Previous results have shown that substitution of residues surrounding the HRV14 VP1-2Apro 
scissile bond (D I K S Y * G L G P) affect autocatalytic cleavage by the 2Apro. Thus, HRV14 2Apro cannot 
accept an Arg (in place of Tyr) in the P1 position of the cleavage site (Sousa et al., 2006). This was 
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examined by studying autocatalytic cleavage reaction of the eIF4GI cleavage site of HRV2 2Apro (T L S 
T R * G P P R), which is not recognized by the HRV14 2Apro. During investigation of these 
substitutions, Arg was determined to be responsible for the lack of cleavage of the eIF4GI cleavage 
site by the HRV14 2Apro (Sousa et al., 2006).  
In another approach, recent results from Karla Kirkegaard and David Neubauer (both 
pers.comm.) suggest that the activity of 2Apro may also be influenced by the 2B protein. Several PV1 
escape mutants, which showed resistance to the specific 2Apro inhibitor zVAM.fmk, were identified as 
mapping to a mutation in the 2B (Kirkegaard, pers.comm.). Furthermore, HRV14 VP1-2Apro-2B 
containing a single mutation (Ile to Asn at position 94 in 2B) in the C-terminal region of the 2B was 
unable to perform the cis-cleavage event (Neubauer, pers. comm., Figure 23).  
 
Figure 23 Proteolytic activity of HRV14 VP1-2A-2B with the mutation I94N in the 2B. Translation into protein was 
monitored at 30°C by using rabbit reticulocyte lysate which were programmed with RNA (10 ng/µl) coding for VP1-2A
pro
. As 
a negative control water instead of RNA was used. At indicated time points 10 µl aliquots were taken and translation 
reaction were stopped by adding an ice-cold stop solution containing 25 µl 2x Laemmli sample buffer, 15 µl H2O and 1 µl 
unlabeled methionine/cysteine (20 mM). Viral proteins were separated on a 17.5% Dasso & Jackson PAA gel and visualized 
by fluorography after an exposure time of 16 hours. 
14
C labeled CFA.626 (Amersham) was used as a size marker (M) and size 
is shown in kDa. Uncleaved VP1-2A
pro
 and the cleavage products VP1 and 2A
pro
 are marked by arrows. This experiment was 
performed by David Neubauer.  
 
These findings strongly support the idea that at least in vitro not only the C-terminal part of 
the VP1 (cleavage site of the 2Apro) plays an important role in the proteolytic activity of the HRV14 
2Apro, but that also the adjacent protein on the polyprotein, 2B, may also influence the properties of 
the 2Apro. Figure 24 shows localization of the VP1 Y289R and the 2B I94N mutation on the HRV14 
genome. 
 
Figure 24 Location of the mutations VP1 Y289R and 2B I94N on the HRV14 genome. Mutations are indicated by an 
asterisk. VP1 belongs to the structural proteins (P1, red), whereas 2B belongs to the non-structural proteins at the P2 region 
(dark blue). P3 is shown here in light blue. Picture made with Photoshop.  
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4.7 ISOLATION AND CHARACTERIZATION OF HRV14 SECOND SITE 
REVERTANTS 
To monitor the effect of the VP1 Y289R and 2B I94N mutation in vivo, HeLa cells were 
transfected with HRV14 full length constructs containing one of these two mutations. Plasmids with 
the full length constructs and mutations were provided by David Neubauer. As described in chapter 
4.5, structurally important residues in the 2Apro should be identified which restore the proteolytic 
activity of the 2Apro.  
 
4.7.4 GROWTH PHENOTYPE OF HRV14 VP1 Y289R AND 2B I94N MUTANT VIRUS 
AFTER TRANSFECTION 
After the transfection of HeLa cells with HRV14 wt and maintaining both mutants at 34°C for 
three days, plaques were visible under the agar on HeLa monolayers.  
 
Figure 25 Effect of mutations on HRV14 growth and spread. Plaque phenotypes on HeLa cells of HRV14 wt and mutant 
viruses are shown. HeLa cells were seeded one day prior to transfection. 1200 ng RNA was transfected at 34°C for 25 
minutes and incubated at 34°C for three days under agar overlay: an uninfected well, cells transfected with HRV14 wt, 
HRV14 2B I94N or HRV14 VP1 Y289R are shown. 
 
As can be seen in Figure 25, the 2B I94N virus displayed plaques which are about equal in size 
to those formed by the wild-type HRV14. However, the mutant that contained the VP1 Y289R 
mutation consistently produced smaller plaques than the wild type after the first transfection.  
 
4.7.5 LOCALIZATION OF SECOND SITE REVERTANTS OF THE HRV14 2B I94N 
MUTANT 
Plaques were then isolated from both mutant viruses and the VP1-2A-2B region sequenced as 
described in 4.5.2. Nearly all plaques isolated contained the previously substituted amino acid 
change: VP1 Y289R or 2B I94N. This experiment shows that viruses carrying one of these mutations 
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are able to self-process the polyprotein by the 2Apro in vivo and therefore replicated in HeLa cells. No 
second site revertants could be identified for the HRV14 VP1 Y289R. In the case of HRV14 2B I94N, 
two second site revertants in 2Apro (M17T and P4H) could be isolated by plaque purification. On the 
basis of the HRV2 2Apro structure (Petersen et al., 1999), the mutated residues identified from the 
isolated plaques were mapped. Sequence alignment show Arg15 (HRV2) as the corresponding 
residue to Met17 (HRV14) and Asp4 (HRV2) as the corresponding residue to Pro4 (HRV14). The 
locations of the second site revertants on the HRV2 2Apro are shown in Figure 26.   
 
Met at position 17 in the HRV14 2Apro is not a highly conserved residue; the corresponding 
position is occupied by an Arg in other rhinoviruses, a Cys in poliovirus and a Val in coxsackievirus. In 
this second site revertant, it was changed to Thr. This mutation is a single base transition mutation, 
where A T G is converted into A C G (underlined residue shows the mutated base). 
In the second mutant, Pro at position P4’ of the cleavage site was changed to His. Poliovirus 
and coxsackievirus both contain His at position P4’ of the cleavage site as well. However, these 
viruses have also a different amino acid at position 94 in the 2B protein; poliovirus encodes a Val and 
coxsackievirus an Ala at this site. This mutation is a single base transversion mutation, where C C T is 
converted into C A T.  
 
  
 
Figure 26 Locations of second site revertants in the 2A
pro
 from the HRV14 2B I94N mutant. HeLa cells were infected with 
HRV14 2B I94N, which was unable to self-process itself in vitro. After the infection period of 90 minutes, cells were 
overlayed with a semi-solid agarose medium, which should inhibit spreading of virus from one location to the other and 
incubated for three days. Plaques were then isolated and used to infect a new population of cells. After three rounds of 
plaque purification, RNA was reverse transcribed by Superscript III Reverse Transcriptase and cDNA was sent for 
sequencing. Two second site revertants in the 2A
pro
 could be identified. Here, the crystal structure of HRV2 was used for 
modeling of the mutations identified. A)  2A
pro
 M17T: Here R15 of the HRV2 structure is thought to correspond to the M17 
of the HRV14 structure and is highlighted in red. B) 2A
pro
 P4H: Here D4 of the HRV2 structure is thought to correspond to 
the P4 of the HRV14 structure and is highlighted in red. The active site residues: His18, Asp35 and Cys106 are shown in light 
yellow. Created with PyMol (DeLano, 2002) using the PDB ID code 2HRV.  
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4.8 KINETICS FOR VIRUS GROWTH FOR SELECTED HRV14 VP1 
Y289R AND 2B I94N MUTANTS AND SECOND SITE REVERTANTS 
As shown in vitro (see Figure 23), the presence of a single mutation in an adjacent protein on 
the polyprotein is able to completely abrogate the activity of HRV14 2Apro. Thus, the substitution of 
Tyr to Arg at residues 289 in the VP1 protein and the substitution of Ile for Asn at residue 94 in the 2B 
protein both influence the properties of the 2Apro in vitro. However, in vivo data suggests that viruses 
bearing one of these mutations are capable of replication in cells and are also able to infect 
surrounding cells. Although 2Apro of virus carrying the mutation I94N in the 2B protein seems to be 
able to cleave itself off the polyprotein as several plaques could be isolated carrying the mutation, 
two mutants were identified carrying an additional mutation in the 2Apro protein. In a further 
experiment, we wanted to monitor and compare growth kinetics of the wt HRV14 virus, the single 
site mutants and the mutants carrying an additional second site mutation. 
The kinetics viral growth of HRV 14 wild type, mutant (2B I94N or VP1 Y289R) and second site 
revertants (2A M17T 2B I94N and 2A P4H 2B I94N) are shown in Figure 27 - 31. For each time point 
and each viral mutant, three individual experiments were performed and the mean values and 
standard deviations were calculated from those results. The titer of extracellular or intracellular virus 
of each mutant at indicated time points after the infection was compared to that for wt HRV14 to see 
whether the mutations have any influence on the replication rate and on the maximal yield of viral 
infection.  
 
Figure 27 Kinetics of intracellular virus growth for HRV14 single mutants and HRV14 wt. HeLa cells were infected at a 
multiplicity of infection of 1 with HRV14 encoding wt or the mutant VP1 (Y289R) or the mutant 2B protein (I94N). The cells 
were incubated at 34°C for 0, 3, 6, 8, 24 and 48 hours post-infection. At indicated time points, virus supernatant containing 
extracellular virus was transferred to a new tube. To the remaining cells, fresh infection medium was added, and virus was 
harvested by three repeated freeze/thaw cycles to break up the cells and to release intracellular virus. Virus titers (pfu/ml) 
were measured by performing a TCID50 and were plotted as a function of time post-infection. Viral titers were measured 
for each virus and each time points three times and the mean values and the standard deviations were calculated. 
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Figure 27 shows the growth kinetics of intracellular wt and single mutant viruses. The titer at 
the first two time points (0 and 3 hours) is very slightly reduced for the mutant viruses compared to 
HRV14 wt. As no replication has taken place in this early phase of infection, the titer only comes from 
virus originally bound to the cells in the 90 minutes of infection or attachment period. After about 6 
hours viral replications is visible. Here, wt virus shows a titer more than 1 log higher than both of the 
mutant viruses. After 24 hours, the maximal titers are reached. No apparent difference between wt 
(black) and the 2B mutant (dots) could be detected here. However, the VP1 mutant (hatched) shows 
a reduced viral growth compared to that of the wild type. Viral titers of VP1 mutants reached about 1 
log less than wt virus. Afterwards the titer started to decrease again. The reason for this is that, when 
all cells are lysed, no further replication of the virus is possible and at 34°C the newly synthesized 
virus particles are unstable and/or are degraded. The maximal yield is nearly the same for the 2B 
mutant as for wild-type, so replication in vivo itself does not seem to be affected by that mutations. 
Viral titers for the VP1 Y289R mutant showed a small decrease in viral replication. However, this 
decreased rate cannot explain the very small plaque sizes of these viruses (compare with Figure 25).  
The titer of extracellular virus is shown from intracellular virus in Figure 28. In the case of the 
extracellular virus, the difference between HRV14 wt and mutant levels is even less apparent than in 
the case of intracellular virus, suggesting that after the replication has started, approximately the 
same amount of virus is produced and replication in vivo is not greatly affected by the mutations. 
 
 
Figure 28 Kinetics of extracellular virus growth for HRV14 single mutants and HRV14 wt. HeLa cells were infected at a 
multiplicity of infection of 1 with HRV14 encoding wt or the mutant VP1 (Y289R) or the mutant 2B (I94N). The cells were 
incubated at 34°C for 0, 3, 6, 8, 24 and 48 hours post-infection. At indicated time points virus supernatant containing 
extracellular virus was separated from cells containing intracellular virus. Virus titers were measured by performing 
TCID50’s. Viral titer (pfu/ml) was plotted as a function of time post-infection. The mean value and the standard deviation 
were calculated from three independent measurements.  
 
In the next step, the growth kinetics of the second site revertants bearing the 2B I94N 
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original 2B I94N single mutant and to the HRV14 wt were measured. The results of this comparison 
are shown in Figure 29 and 30.  
 
 
  
 
Figure 29 Kinetics of intracellular virus growth for HRV14 mutants carrying a second site mutation in the genome 
compared to the HRV14 2B I94N single mutation and the HRV14 wt. HeLa cells were infected at a multiplicity of infection 
of 1 with HRV14 encoding wt, the mutant 2B (I94N) or one of the two HRV14 2B I94N mutations bearing a second mutation 
in the 2A
pro
: Met to Thr at position 17 of the 2A
pro
 and Pro to His at position 4 of the 2A
pro
. Same procedure as described in 
Figure 27.  A) Bar chart and B) line chart.  
 
 
It was expected that the second site revertants show a similar kinetic pattern than HRV14 wt 
or at least replicate faster than the single mutant.  However, the results of the growth kinetics 
differed from the expected outcome. Interestingly, kinetics shows that viral titers in all time points 
(except for the time points of 48 hours after post-infection) are about 1 to 1.5 logs higher for HRV14 
wt than for HRV14 2B I94N second site revertants bearing a mutation in the 2Apro: Met to Thr at 
position 17 of the 2Apro and Pro to His at position 4 of the 2Apro. In addition, also by comparing 
kinetics of the second site revertant to the 2B I94N starting mutant, it can be seen that the single 
mutant replicates to higher yields than the second site revertants. Thus, no positive effect on the 
viral replication by these second site revertants could be identified. We therefore concluded that the 
second site mutations were not introduced as a response to the 2B I94N mutation.  
For a better comparison, the kinetics of growth of intracellular virus for HRV14 mutants 
carrying a second site mutation in the genome compared to wt HRV14 and the original HRV14 2B 
I94N mutant is shown as linear graph in Figure 29B.  
Titer of extracellular virus is shown separately from intracellular virus in Figure 30.  
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Figure 30 Kinetics of extracellular virus growth for HRV14 mutants carrying a second site mutation in the genome 
compared to the HRV14 2B I94N single mutation and the HRV14 wt. HeLa cells were infected at a multiplicity of infection 
of 1 with HRV14 encoding wt, the mutant 2B (I94N) or one of the two HRV14 2B I94N mutations bearing a second mutation 
in the 2A
pro
: Met to Thr at position 17 of the 2A
pro
 and Pro to His at position 4 of the 2A
pro
. Same procedure as described in 
Figure 28.  
 
Again some unbound virus is present at the first three time points (0, 3 and 6 hours post-
infection), but titers of extracellular virus do not rise, suggesting that no new virus is produced in this 
time span. Titers of extracellular virus carrying a second site mutation in the 2Apro after 24 hours 
post-infection are still 1 to 1.5 logs lower than HRV14 wt or single mutant. After 48 hours, the mutant 
2B I94N 2A P4H has achieved the same titer as the original mutant whereas 2B I94N 2A M17T is still 
one log lower. 
Although we were hoping to isolate second site revertants bearing an additional mutation in 
the 2Apro that has a positive effect on the proteolytic activity, this was not the case. We suppose that 
these isolated second site revertants have probably not been introduced as a response to the 2Apro 
cleavage inhibition due to the 2B I94N mutation but either due to random introduction of a mutation 
by the error prone RNA polymerase and/or because multiple continuous passages also might reduce 
fitness through random mutations (Domingo and Holland, 1997).  
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5 DISCUSSION   
About 30% of all common colds are caused by HRV. Moreover, it is one of the most frequently 
and recurring infectious diseases in humans with a major economic impact. Although infections are 
normally relatively mild, billions are spent every year for treatment of the common cold (Monto and 
Sullivan, 1993). However, little progress in the generation of vaccines or anti-viral compounds has 
been made until now, due to the large variety of HRV serotypes. This makes it rather difficult to 
produce a vaccine against HRVs. Antibodies against one serotype are often not able to neutralize 
another serotype (Whitton et al., 2005). Another option would be the development of antiviral 
inhibitors against one or more of the non-structural proteins of HRVs. The 2Apro of Enteroviruses 
seem to be potential targets as they perform a highly conserved cleavage process during infection. 
Although the cleavage event is rather conserved, the proteins responsible for it nevertheless vary 
greatly among the different serotypes. Therefore, no consensus sequence of these cleavage sites 
could be determined for HRV 2Apro. However, some positions could be determined to be rather 
conserved. Gly at position P1’ seems to be absolutely required for the cleavage process. Another 
highly preferred residue is Thr at position P2, forming a hydrogen bond to Ser83 which leads to an 
important rotation of Tyr85 and therefore to substrate binding. These identified requirements 
provide the basis to state that the 2Apro is a specific proteinase. Understanding substrate specificity of 
rhinoviral 2Apro would be of great importance for the development of effective inhibitors. 
The work in this thesis was made to gain deeper insight in the 2Apro cleavage event of HRV1A 
and HRV14. Mutational analysis of the cleavage site of HRV1A should lead to the identification of 
residues important for the cleavage process. The generation of second site revertants should help to 
further identify structurally important positions that allow the recovery of functionality and also shed 
light on the substrate requirements of the 2Apro of human rhinoviruses.  
 
5.1 PROTEOLYTIC SELF-PROCESSING PERFORMED BY  HRV1A 2APRO  
The first part of this thesis centered on illuminating the substrate specificity of the HRV1A 2Apro 
and therefore which residues were required to perform the autocatalytic cleavage between the         
C-terminus of VP1 and its own N-terminus. The HRV1A 2Apro cleaves its own polyprotein at T I T T A * 
G P S D, whereas HRV14 2Apro cleaves at D I K S Y * G L G P. Therefore cleavage sites of these two 
rhinoviruses differ strongly at position P5, P3, P1, P2’-P4’. The exchange of the wild type residues at 
the VP1-2Apro cleavage junction of HRV1A with the corresponding residues of the HRV14 cleavage 
site led to a complete abrogation of proteolytic activity (Figure 18). The HRV1A 2Apro is therefore not 
able to accept the VP1-2Apro cleavage site of HRV14. We then tried to determine which part was 
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responsible for this discrimination. However, neither the introduction of the HRV14 VP1 part (P5-P1), 
nor mutating the 2Apro part (P2’-P4’) alone stopped the self-processing reaction; it was only slightly 
delayed (Figure 19A and B). We therefore concluded that combination of mutations on both sides of 
the cleavage junction are necessary to stop the HRV1A 2Apro in performing this cis-cleavage event. As 
a consequence we tried to mutate combinations on both sides of the cleavage junctions in HRV1A 
2Apro. To choose the appropriate residues for these changes, we first had a closer look at the residues 
present in the HRV14 VP1-2Apro cleavage junction in comparison with those of HRV1A.  
Several substrate specificity studies have been performed with the HRV2 2Apro (Skern et al., 
1991; Sommergruber et al., 1992), which is assumed to be similar to the HRV1A 2Apro, as it shows a 
sequence identity of 88% and a positive score of 96% (indicates how many amino acids are at least 
similar). This is shown in Figure 31A. The HRV14 2Apro, however, shares only a sequence identity of 
43% to the HRV1A 2Apro sequence (Figure 31 B).  
 
 
Figure 31 Comparison of the 2A
pro
 of HRV1A with HRV2 and HRV14. A) HRV1A and HRV2, both from the human 
rhinoviruses group A share an amino acid sequence identity of 88%. B) HRV1A compared to HRV14, which belongs to the 
group B of human rhinoviruses share only a sequence identity of 43%.  The active site residues of HRV2 2A
pro
 are marked 
with a red arrow: His, Asp, Cys.  The residues coordinating the zinc ion are marked with a dark blue arrow.  The sequences 
were taken from the database www.ncbi.nlm.nih.gov. Sequence IDs: AY458604 (HRV-A 1a), X02316.1 (HRV-A 2), X01087 
(HRV-B 14). The sequence alignment was made online using ClustalW (http://www.ebi.ac.uk/Tools/ msa/clustalw2/) and 
edited with the programme BioEdit. 
 
The cleavage site of HRV1A 2Apro differs from HRV2 2Apro by only one amino acid, a Thr at 
position P5 instead of an Ile (Figure 12 in chapter 1.6.3). The contribution of various amino acids to 
the substrate specificity of the HRV2 2Apro has been extensively studied. These revealed that HRV2 
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2Apro has an absolute requirement for Gly at position P1’ and a strong requirement for Thr at position 
P2.   
Amino acids at position P2 of a synthetic peptide, such as Ala, Val, Lys, Ile, Phe, Gly, Tyr, Asp, 
Glu were shown to be not processed at all and mutating this site to Ser, Pro, Asn, Gln, Lys, Arg or His 
resulted in a highly reduced cleavage efficiency (Sommergruber et al., 1992). Therefore, we 
concluded that the Ser at position P2, which is present in the HRV14 2Apro wt cleavage site and 
replaces Thr in the HRV1A constructs, is maybe one reason for the lack of cleavage. Petersen et al. 
(1999) provided an explanation for this, as Thr in HRV2 was found to form a hydrogen bond with 
Ser83 and thereby facilitate in a rotation of Tyr85 away from its original position, where it was 
stacked upon His18. This leads to the formation of an S2 site. This hydrogen bond seems to 
compensate for this rotation after the substrate has bound (Petersen et al., 1999).  
It was further shown that the HRV2 2Apro cleaved substrates with a Tyr at position P1 even 
better than with the wt Ala. Met at this position resulted in an even higher relative cleavage 
efficiency in respect to the peptide with the wt cleavage sequence. Besides this, several other 
residues were shown to be accepted at this position, such as Phe, Thr, Lys, Arg, even though not as 
wt Ala (Sommergruber et al., 1992). Other residues, such as Pro, Asp, Glu, Val, Asn and Gln were not 
accepted at this position. Tyr at position P1 seems therefore not to be responsible for the cleavage 
inhibition.  
Substrates with a Lys at position P3 were shown to be cleaved when a Thr at P2 was also 
present (Skern et al., 1991). However, substrates with a Lys at P3 were not cleaved when a Ser or Asn 
instead of a Thr were present at P2 (Sommergruber et al., 1992).  
The role of the conserved residues in the P’ region has also been examined by mutagenesis. 
Although Gly at P1’ position is conserved in all Enteroviruses, it has been shown that poliovirus 2Apro 
is able to accept Ala and Ser in the P1’ position of the cleavage site (Hellen et al., 1992). However, 
many studies have shown that HRV2 2Apro is not able to accept any substrate/peptide with an amino 
acid P1’ substitution. Amino acids tested included Phe, Thr, Asp, Lys, Glu, Trp (Skern et al., 1991; 
Sommergruber et al., 1992).  
In addition, it has been shown that peptides with Asp, Phe Thr, Lys at position P2’ are cleaved 
with a two to five fold less efficiency than with a Pro at this site (Sommergruber et al., 1992). Thus, a 
negative influence of the exchanged Leu at this P2’ site could be very likely.  
On the basis of these considerations, we decided that residues at position P3, P2, P1 on the 
one side and P1’ and P2’ on the other side were the most important residues. To this end, we aimed 
to determine the exact residues exchanged which were required to be mutated to stop proteolytic 
activity of the HRV1A 2Apro. We therefore exchanged residues on both sites of the VP1-2Apro cleavage 
junction, either mutating P3-P1 (ThrThrAla to LysSerTyr) in addition to mutating Pro at P2’ with Leu 
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or only P2-P1 (ThrAla to SerTyr) in combination with P2’ (Pro to Leu). These mutations were 
determined to severely impair self-processing (Figure 20A and B). As a very slight cleavage could be 
monitored with the mutant 4 (P2-P1 and P1’), we concluded that Lys at position P3 might be 
responsible for a slight decrease in self-processing efficiency. However, Ser at P2 and Leu at P2’ seem 
to be important to abrogate cleavage. This leads us to the assumption that Thr at P2 and Pro at P2’, 
are important substrate requirements for the HRV1A 2Apro, in addition to the completely conserved 
Gly at P1’. 
We further wanted to investigate whether it was possible to exchange Gly at position P1’ with 
a slightly larger amino acid, Ala. Ala has a methyl group as side chain in place of a single hydrogen 
atom. In our in vitro studies, we found that HRV1A 2Apro is not able to process the polyprotein when 
the cleavage sequence contains an Ala at the P1’ position. Petersen et al. (1999) explained that this 
absolute requirement of Gly at P1’ could be due to Leu19 that blocks the access of any residues other 
than Gly to the S1’ site (Petersen et al., 1999). However, by modeling a substrate into the binding 
cleft of HRV2 2Apro and changing the side chain of Gly to the side chain of Ala we can see that Leu19 
is too far away to block the access of Ala. Figure 32A shows a model of an oligopeptide substrate 
occupying subside S4-S1’. This peptide, consisting of five residues, corresponds to the sequence of 
the polyprotein at the junction of VP1 and 2Apro of HRV2 (ITTA*G). Figure 32B shows a substrate 
where the Gly at the P1’ position was replaced by Ala.  
 
 
  
Figure 32 Substrate modeled into the HRV2 2A
pro
 binding site. The atomic color coding for the enzyme is light blue for the 
main chain, dark blue for the nitrogen and red for the oxygen. For the substrate, color coding is rose for the main chain, 
dark blue for the nitrogen and red for the oxygen. Tyr85 of the enzyme which has been rotated out of the binding site after 
the formation of a hydrogen bond between Thr at P2 (substrate) and Ser83 (enzyme) is shown in turquoise. Hydrogen 
bonds are designated by dashed, grey lines between donor and acceptor atoms. A) Drawing showing a pentapeptide with 
corresponding wt residues (I T T A * G) bound to the subside S4-S1’ of the HRV2 2A
pro 
binding cleft. B) Drawing showing a 
mutated oligopeptide where the Gly at position P1’ is exchanged by Ala (I T T A * A). The dots in this figure show the area 
including hydrogen atoms of the residues Tyr85 and the P1’ Ala to see that whether they sterically hinder each other. This 
explains why Ala at the P1’ is not accepted by the HRV1A 2A
pro
. The distance between some adjacent molecules was 
calculated and shown by dashed, red lines. Model was generated with the program PyMol (DeLano, 2002). Precise 
explanation of how the model was generated is described in the text.   
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This model was generated as described by Petersen et al. 1999. Briefly, this was produced on 
the basis of the Streptomyces griseus proteinase B (SGPB) in complex with the third domain of the 
turkey ovomucoid inhibitor OMTKY3 (Read et al., 1983). This proteinase shows a chymotrypsin-like 
proteinase fold, and although sequence identity between SGPB and HRV2 2Apro is less than 20%, it 
was chosen as a representative structure of the canonical substrate binding. Indeed, the structure of 
the SGPB differs from the HRV2 2Apro only in the N-terminal part. The binding of the SGBP to the 
OMTKY3 involves an antiparallel β-strand interaction between P2-P4 from the inhibitor with the eII 
strand from the proteinase, typical for chymotrypsin-related proteinases (Bode and Huber, 1992).  
The interaction of the HRV2 2Apro is thought to be similar.  
To design the substrate binding site, residues of the HRV2 2Apro were structurally aligned with 
those of  SGBP via the pair fitting mode of PyMol (DeLano, 2002). To this end, residues 101-106 
(oxyanion hole) and residues 120-124 (eII strand) of the HRV2 2Apro (PDB code: 2HRV) were aligned 
with residues 192-198 and residues 212-216, respectively, of the SGPB-OMTKY3 complex (PDB code: 
3SGB). Residues 14-19 from the OMTKY3 inhibitor correspond to the P4-P1’ site; side chains of this 
residues were replaced with the side chains of the HRV1A 2Apro substrate and side chains of mutated 
substrates.  
According to the measurement in PyMol, the methyl group of Ala at the P1’ position of the 
substrate is not blocked by Leu19 as it is 4.5 Å distant. However, in the modeling in Figure 32B, it can 
be seen that Tyr85, which was rotated out of the substrate binding site to form the S2 pocket is 
rather close to the side chain of the P1-Ala. The distance between the Cβ atom of the methyl group 
of Ala to the C5 and C6 atom of Tyr85 was calculated to be 2.6Å and 3.0Å. With the dotted structure, 
in which also hydrogen atoms are considered, it can be seen that these structures overlap.  
We therefore predict that not Leu19, but rather Tyr85 is responsible for the discrimination of 
any larger amino acid than Gly. As Tyr85 is rotated out because the Thr at position P2 forms a 
hydrogen bond with Ser83, the question arises whether Ala would be accepted when Thr at position 
P2 was mutated to another amino acid. However, as described above, nearly all amino acids 
exchanged at this site were shown to inhibit the self-processing of the HRV2 2Apro. In fact, residues 
larger than Ala would also be blocked by Leu19. PV 2Apro is in contrast able to accept an Ala and 
several other smaller residues, such as Ser at P1’ (Hellen et al., 1992). In addition, several amino acids 
are also accepted by the PV 2Apro at position P2, such as Ala, Ser, Asn, Gln and Pro. However, Tyr85 is 
also conserved in PV. This suggests that substrate recognition does differ between HRV and PV. 
On the contrary, the 2Apro of HRV2 was able to perform trans-cleavage of Nup62 when an Ala 
was present at P1’ (Park et al., 2010). However, none of these cleavage sites contained in addition 
Thr at P2. This could indicate that Ala can be accepted at P1’ when no hydrogen bond between the 
substrate (Thr at P2) and the enzyme (Ser83) is formed and therefore no rotation of Tyr85 is 
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accomplished. However, the question remains whether the hydrogen bond formation and 
subsequent rotation of Tyr85 is vital for the substrate binding. To determine if Tyr85 is required to 
rotate out of the substrate binding site, a crystal structure will be needed that shows whether a 
hydrogen bond is formed with a different amino acids (such as Thr or Asn), which are also able to 
participate in a hydrogen bond. Indeed, the hydrogen bond with Tyr85 has not even been shown.  
In short, we identified several residues in the cleavage site of the HRV1a VP1-2Apro junction as 
being detrimental for carrying out the self-processing reaction. These residues are summarized in 
Table 18. Cleavage sites, which were chosen for the further experimental procedures, are marked 
with an arrow.  
 
 
 
 
 
 
 
 
5.2 STRUCTURAL CHANGES OF HRV1A ESCAPE MUTANTS 
Three different cleavage sites were introduced into the full length HRV1A clone: D I K S Y * G L 
G P, T I T S Y*G L S D and T I T T A * A P S D. All of these sites were previously shown to inhibit the 
self-processing reaction of the HRV1A 2Apro. By transfecting HeLa cells with viral RNA containing the 
desired mutations, virus with second site revertants should be generated from viral offspring. Virus 
could be isolated from viral plaques from all RNAs except for the virus carrying the full wt cleavage 
site of the HRV14 2Apro. This full HRV14 2Apro cleavage site mutation does not only severely impair 
self-processing in vitro; there are probably also too many changes necessary to restore cleavage 
activity.   
In the case in which combinations of the HRV14 2Apro cleavage site were exchanged (T I T S Y*G 
L S D), several viral plaques were isolated. We could deduce three reactions of how the virus reacted 
to the mutated cleavage sites that in vitro had inhibited the self-processing of the 2Apro (see Table 
14).  
Six out of ten isolated viral plaques changed the Tyr at position P1 to Cys. This was rather 
surprising, as Tyr at position P1 (alone) was shown to be cleaved even better by HRV2 2Apro 
Serotype VP1 
P5 P4 P3 P2 P1 
 2Apro 
P1’ P2’ P3’ P4’ 
Cleavage 
efficiency 
HRV 1a wt  T     I    T    T    A *  G    P     S     D ++ 
HRV 14 wt   D    I    K    S    Y *  G    L     G     P - 
HRV 1A mutant 1  D    I    K    S    Y *  G    P     S     D + 
HRV 1A mutant 2  T     I    T    T    A *  G    L     G     P + 
HRV 1A mutant 3  T     I    K    S    Y *  G    L     S     D - 
HRV 1A mutant 4  T     I    T    S    Y *  G    L     S     D - 
HRV 1A mutant 5  T     I    T    T    A *  A    P     S     D - 
Table 18 Cleavage sites which were shown in vitro to inhibit self-processing of HRV1A 2A
pro
. Arrows indicate cleavage 
sites which were further introduced into the full length HRV1A clone for transfection of HeLa cells.  
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(Sommergruber et al., 1992). Figure 33A shows a representation of a model of the previously 
mutated substrate occupying subside S4-S1’ (I T S T * G). Although Leu at position P2’, which 
replaced the wt Pro, plays also a role in the inhibition of substrate binding, it is not shown in the 
model. Figure 33B shows the substrate when the Tyr at P1 was mutated to Cys by escape mutants. 
This second site mutation was isolated several times in independent experiments. Hence, the 
presence of Cys at P1 (instead of Tyr) is possibly compensating the harmful effect of Ser at P2 and 
Leu at P2’. By looking at detail at the single nucleotide bases, we identified Cys as being the most 
likely amino acid possible by a single base transition mutation. Mutation of only one purine base 
change (TATTGT) is required to change Tyr into Cys (Table 15).  
 
 
 
 
 
 
Figure 33 Drawing of a mutated substrate modeled into the HRV2 2A
pro
 binding site. The atomic color coding is the same 
as in Figure 32. Although there is no crystal structure with a different amino acid than Thr at P2, we indicate here that a 
hydrogen bond is also formed between Ser at P2 and Ser83 that subsequently leads to the rotation of Tyr85. A) Drawing 
showing a mutated oligopeptide with corresponding residues I T S Y * G. B)  Drawing showing the second site revertant, 
where the Tyr at P1 was changed to Cys (shown in dark red).The sulfhydryl group of this Cys is marked by an arrow as it is 
hard to see. Precise explanation of how the model was generated is described in the text.  
 
The final residue of the VP1 thus becomes Cys and not Tyr in this mutant. VP1 is one of the 
outer capsid proteins and is assembled in the cytosol of the infected cell. Figure 34A and B shows the 
location of the mutated Cys in the 5S protomer structure of HRV1A. In Figure 34C and D, the 
originally mutated Tyr at position 289 in the VP1 protein (instead of the wt Ala) is compared to the 
mutated Cys at position 289 as isolated by several escape mutants.  
As it is the last residue (C-terminus of VP1) it is at a particularly flexible region. Although we do 
not think it is very likely to happen, as the cytosol, a reducing environment, destabilizes disulfide 
bonds, we could nevertheless imagine that the Cys forms a disulfide bridge with another Cys of a VP1 
molecule of a neighboring particle. However, this would probably lead to an inhibition of viral 
release.  
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Figure 34 Location of the mutated Cys 289 of VP1 in the 5S protomer structure of HRV1A. A) Ribbon diagram and B) 
surface representations of the 5S protomer; position 289 on VP1 (last residue before the cleavage junction) is marked by an 
arrow. The color for this residue is black in A and grey in B, C and D.  C) Drawing of the mutated Tyr (instead of the wt Ala). 
D) Drawing of the mutated Cys as isolated by several escape mutants. Color coding: VP1 (blue), VP2 (green), VP3 (red) and 
VP4 (light orange). Created with PyMol (DeLano, 2002) using the PDB ID code 1R1A .  
 
The second way the virus reacted to the exchanged cleavage site (T I T S Y * G L S D) was by 
mutating the Leu at P2’ back to the wt Pro, maintaining the Ser at P2 and Tyr at P1. This is also a 
single base transition mutation from CTA to CCA. This is not a particularly unexpected result, as it was 
shown in vitro that combinations of mutations on both sides of the cleavage junction are necessary 
to inhibit cleavage (Figure 19A and B). Therefore, mutating Leu back to the original Pro will recover 
self-processing as the P’ side now has the wt sequence. 
For the third way, we isolated one virus which carried the original mutated cleavage site. Thus, 
we concluded, that although cleavage is not very likely to happen, the 2Apro is not 100% inhibited by 
these changes. This was also shown in vitro (Figure 20B). In addition, compensatory mutations 
outside the VP1/2A/2B region cannot be excluded. 
As a summary, identified viruses had either a second site mutation in the cleavage site (Tyr at 
P1 to Cys), changed an amino acid back to the original sequence (Leu at P2’ to Pro) or carried the 
original mutant cleavage site (T I T S Y * G L G P). 
In future experiments, we would like to look at the in vitro cleavage to see whether these 
escape mutants are able to cleave VP1-2Apro during in vitro translation. Furthermore, we would like 
to investigate whether Ala would be accepted at the P1’ if the Thr at P2 was changed to a different 
residue, which is not able to facilitate in a hydrogen bond with Ser83. In addition, we would like to 
monitor growth kinetics of the isolated escape mutants, to investigate whether there is a difference 
in replication efficiency to wt HRV1A 2Apro. 
We can only speculate why it is easier for the virus to mutate residues in the cleavage site than 
somewhere in the active site or substrate binding site. Possibly, to change the mechanism in the 
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active site, several mutations and probably also base transversions must occur. Single base transition 
happen more frequently than multiple base transitions or transversions. In the case in which the full 
cleavage site was replaced by the corresponding amino acids of HRV14, the virus was not able to 
introduce any successful mutation(s), probably due to the multiple mutations that would be 
necessary to perform the self-processing reaction.  
Several viral plaques were also isolated after infecting cells with the TI T T A * A P S D cleavage 
site mutant. All of the sequences showed that the Ala at P1’ was mutated back to the original Gly. As 
described in Figure 32A and B, we suppose that Ala is blocked by the rotated Tyr85 (see chapter 5.1). 
We therefore conclude that Gly at the P1’ position is an absolute requirement for performing the 
self-processing reaction of rhinoviral 2Apro in cis.  
 
5.3 INVESTIGATING THE HRV14 2APRO  
As described in results, the mutations in the protein VP1 (Y289R) and in the 2B (I94N) were 
shown to prevent the HRV14 2Apro from cleaving itself off from VP1-2Apro in vitro (Sousa et al., 2006; 
Neubauer et al., 2009).  
Again, viral RNA carrying the desired mutations was transfected into HeLa cells and viral 
offspring was isolated. Sequence analysis revealed that, although self-processing was inhibited in 
vitro, it did not have such a detrimental effect in vivo, since several viral plaques were isolated 
carrying only the introduced mutation. One difference could however be detected in the plaque size 
of virus carrying the VP1 Y289R mutation. Viral plaque size of these viruses was about three times 
smaller than compared to that of wt HRV14 (Figure 25). Therefore, we first supposed that although 
the VP1 Y289R mutations, which is the last residue before the cleavage junction (P1), is able to be 
cleaved by the HRV14 2Apro in vivo, it leads to a reduced efficiency of cleavage and therefore a 
growth defect of this virus. However, by monitoring growth kinetics only a delay and slight growth 
defect could be determined (Figure 27 and 28). However, this slight growth defect can not explain 
the small plaque size. One explanation could be that these viruses have a defect in spreading or lysis, 
as virus is obviously produced. Furthermore, the defect in spreading could explain why mutant VP1 
Y289R virus could replicate better in liquid medium, where virus is easier transmitted to another cell 
instead in a semi-solid medium.  
Although mutating the Arg at position 289 back to Tyr would only need two base transition 
mutations, no escape mutants were isolated. Figure 35 shows the location of the mutated Arg 289 in 
the VP1 protein of the HRV14 in the viral 5S protomer (Figure 35A and B) and compares the wt Tyr at 
position 289 of VP1 (Figure 35C) to the mutated Arg at position 289 (Figure 35D).  
 
84 
          
 
  
Figure 35 Location of the mutated Arg 289 of VP1 in the 5S protomer structure of HRV14. A) Ribbon diagram and B) 
surface representation of the 5S protomer; position 289 on the VP1 protein (last residue before the cleavage junction) is 
marked by an arrow. C) Drawing of the wt Tyr at position 289 in HRV14. D) Drawing of the mutated Arg at position 289 in 
HRV14 mutants. Color coding is the same as in Figure 34. Created with PyMol (DeLano, 2002) using the PDB ID code 4RHV.  
 
The influence on the growth kinetics of the 2B I94N mutations was even less than for the VP1 
mutation. Kinetics of growth showed a slightly decreased rate in the beginning, but maximum yield 
of virus, which was reached after about 24 hours showed, nearly the same pfu/ml than for wt HRV14. 
Although recent results suggest that the protein 2B is involved in the cleavage event of 2Apro 
(Kirkegaard, pers.comm.; Neubauer et al., 2009), our results show that the self-processing reaction of 
the HRV14 2Apro is not inhibited in HeLa cells. It was surprising that two different escape mutants, 
bearing an additional mutation in the 2Apro, were isolated. One second site mutant changed the Pro 
at position P4 to His, the other changed Met at position 17 to Arg (Figure 26). Although our growth 
kinetics of the 2B mutant did not show any defect, we also monitored the kinetics of the escape 
mutants. Unexpectedly, these mutants grew slower and to a lower yield of maximum virus than both 
the wt HRV14 and the single mutant 2B virus (Figure 29 and 30). This led us to conclude that these 
additional mutations identified in the 2Apro have probably nothing to do with the mutations in the 2B 
and were not introduced to recover proteolytic activity. The quasispecies theory suggests that 
mutations are constantly introduced during viral evolution in the fitness landscape (Wilke et al., 
2001). As RNA viruses replicate with a high mutation rate, they will after some generations develop a 
diverse mutant repertoire (Lauring and Andino, 2010). Darwin stated that this is done to optimize 
fitness and thereby generating an organism which fits, survives and reproduces “better” in the 
existing environment (Orr, 2009). However, Domingo and Holland stated that RNA viruses undergo 
fitness changes during continuous passages, thereby reducing fitness (Domingo and Holland, 1997). 
This may have happened to our second site revertants.  
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The results of this thesis are one step further in the investigation of the exact substrate 
requirement of enteroviral 2Apro. It was demonstrated that inhibition of the intramolecular cleavage 
of the HRV1A 2Apro was achieved by exchanging combinations of residues on both side of the 
cleavage junction. Exchanging only one side resulted solely in a slightly delayed cleavage kinetics. 
However, in vivo experiments, in which escape mutants were isolated, have shown that the 
replacement of one side is enough to recover proteolytic activity of the HRV1A 2Apro. We showed 
that the HRV1A 2Apro accepts a cysteine at the position P1 of the cleavage junction in vivo as several 
escape mutants bearing this change could be isolated.  Although the VP1 Y289R mutation was shown 
to inhibit proteolytic cleavage of the HRV14 2Apro in vitro, we show that this is different in vivo. Even 
though virus with this VP1 mutation could replicate in vivo, we observed a small plaque phenotype, 
which might be due to the presence of the arginine at the P1 position of the cleavage junction of the 
HRV14 2Apro. These experiments suggest that substrate requirements for HRV1A and HRV14 2Apro are 
rather different; therefore the development of specific inhibitors against either protease will be 
required. Thus, further investigations in the substrate specificity of the 2Apro of HRV-A, -B and -C 
viruses will be necessary.  
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6 APPENDIX 
6.1 LIST OF AMINO ACIDS 
 
A Ala Alanine 
C Cys Cysteine 
D  Asp Aspartic acid 
E  Glu Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His  Histidine 
I  Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W Trp Tryptophan 
Y Tyr Tyrosine 
 
6.2 LIST OF ABBREVIATIONS 
  
2A
pro 
Proteinase 2A 
Å Angström 
°C Degrees celsius 
µl  Microliter 
µg Microgram 
aa Amino acid 
Amp Ampicillin 
APS Ammonium peroxidisulfate 
ATP Adenosine triphosphate 
bp Base pair 
cDNA  Complementary DNA 
CIP Calf intestine phosphatase 
CITE Cap-independent translation enhancer 
cre Cis responsive element 
CV Coxsackievirus 
dH2O Deionized water 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid  
dNTP Deoxynucleotide triphosphate 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
eIF Eukaryotic initiation factor  
EMCV Encephalomyocarditis virus 
FCS Fetal calf serum  
 
88 
FMDV Foot-and-mouth disease virus 
g Gram 
h Hour 
HAV Hepatitis A virus 
HeLa Henrietta Lacks’ cells  
Hpi Hours post infection 
HRV Human rhinovirus 
ICAM-1 Intercellular adhesion molecule 1 
ICTV International committee on taxonomy of 
viruses 
IRES Internal ribosomal entry site 
kb Kilobases 
kDa Kilo Dalton 
l Liter 
L
pro
  Leader protease 
LB Luria Bertani 
LDL Low-density-lipoprotein 
LDLR Low-density-lipoprotein receptor 
LGS Lower gel solution 
M Molar  
Min Minutes 
ml Milliliter  
mM Milimolar 
mRNA Messenger RNA 
nt Nucleotide  
NTP Nucleotide triphosphate 
NUP Nuclear pore complex protein 
ORF Open reading frame 
PABP PolyA-binding protein 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction  
PDB Protein Data Bank 
Pfu Plaque forming unit 
PNK Polynucleotide kinase 
PolyA Poly adenylation  
PV Poliovirus 
RNA Ribonucleic acid  
RNase Ribonuclease  
Rpm Rotations per minute 
RRL Rabbit reticulocyte lysate  
RT Room temperature 
SDS Sodiumdodecylsulfate 
SGPB Streptomyces griseus proteinase B 
TAE Tris-acetate-EDTA 
TE Tris-EDTA 
TEMED Tetramethylethylenediamine  
UTR Untranslated region  
UV Ultraviolet 
VLDLR Very low density lipoprotein receptor 
VP Viral protein  
VPg Viral protein genome linked 
Wt Wild type 
zVAD.fmk Benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketone 
zVAM.fmk Benzyloxycarbonyl-Val-Ala-Met-
fluoromethylketone 
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